

# HEALTHCARE SECTOR BULLETIN

June 2015

QUADRIA  
CAPITAL

## HEALTHCARE TRENDS & IMPACT STORIES

---

Country:	Vietnam
Headline:	<b><i>Insurers in tie-up with Malaysian hospitals</i></b>
Summary:	<p>Several Vietnamese insurance companies have signed a Memorandum of Understanding (MoU) with Malaysian hospitals, under which Vietnamese policyholders would have medical insurance cover when they seek treatment at the participating hospitals.</p> <p>The signing ceremony, which took place last week, involved top Malaysian private hospitals, such as the National Heart Institute, Ramsay Sime Darby Health Care and Pantai Hospital Kuala Lumpur, and insurance providers including Post and Telecommunication Joint Stock Insurance Corporation (PTI), Vietinbank Insurance Company (VBI) and Petrolimex Insurance Corporation (PJICO), reported the Vietnam News Agency.</p> <p>In a statement, Allianz Life Malaysia said that Medisafe provides protection for customers in the event of hospitalisation. Available in seven plans, it offers different levels of benefits, ranging from reimbursement for pre and post hospitalisation treatments to home nursing care and ambulance fees. Other important benefits include out-patient treatment for dengue and fee reimbursement for alternative treatment post-hospitalisation such as chiropractic, chiropody, homeopathy, osteopathy or acupuncture which are usually not part of a hospitalisation and surgical insurance coverage.</p>
Link	<a href="http://www.asiainsurancereview.com/News/View-NewsLetter-Article?id=32896&amp;Type=eDaily">http://www.asiainsurancereview.com/News/View-NewsLetter-Article?id=32896&amp;Type=eDaily</a>

---

Country:	India
Headline:	<b><i>Pharma outsourcing leads healthcare BPO market in India</i></b>
Summary:	<p>Pharmaceutical outsourcing market (excluding contract manufacturing services) accounts for about 75 per cent (or \$2.5-3.1 billion) of the India's medical process outsourcing (MPO) segment which is currently estimated at \$3.3-4.2 bn, according to a new Assocham-EY joint study.</p> <p>The recent US regulation on Patient Protection and Affordable Care Act (PPACA) together with the proposed introduction of ICD-10 standards have given impetus to the Indian MPO market. Besides, domestic players are also gradually moving up the value chain in terms of service offerings while maintaining their cost competitiveness.</p> <p>The study, titled 'Medical process outsourcing in India', noted that while the payer outsourcing market constitutes \$700-900 million of India's MPO market, the provider market accounts for the remaining share of about \$100-200 mn.</p> <p>All of these combined, according to the Assocham-EY study, will give a boost to the MPO market, with payer BPO market likely to grow at about 10 per cent year-on-year (Y-o-Y) in the next three to four years globally, provider outsourcing at more than 30 per cent during 2011-2016, and the contract research organisations (CROs) market at 18-20 per cent in the coming years.</p>
Link	<a href="http://www.business-standard.com/content/b2b-pharma/pharma-outsourcing-leads-healthcare-bpo-market-in-india-115062301266_1.html">http://www.business-standard.com/content/b2b-pharma/pharma-outsourcing-leads-healthcare-bpo-market-in-india-115062301266_1.html</a>

---

## HEALTHCARE SECTOR NOTABLE TRANSACTIONS

---

Country: Indonesia

Headline: ***Myanmar's FMI, Indonesia's Lippo roll out \$420m hospital partnership***

Summary: First Myanmar Investments Co Ltd (FMI) and Indonesian conglomerate Lippo Group have officially launched a healthcare joint venture with a \$420 million national roll out in Myanmar.

"Myanmar's economy is rapidly growing and with this comes the demand for high quality international healthcare. The time is right for a premier nationwide hospital network to support the market," said Dr James Riady, CEO of Lippo Group.

The joint venture was touted by the firms as "realisation of an Indonesian-Myanmar ASEAN brotherhood cooperation spirit."

Indonesia's state-owned mining companies Timah and Aneka Tambang and lender Bank Negara Indonesia are already in the process of expanding into the Southeast Asian frontier market. Also, state-owned construction firm Wijaya Karya clinched a \$125-million deal last year.

Links: <http://www.dealstreetasia.com/stories/myanmars-fmi-indonesias-lippo-roll-out-420m-hospital-partnership-8072/>

---

Country: Assam

Headline: ***Apollo buys stake in Assam Hospitals***

Summary: Chennai-based Apollo Hospitals Enterprise Ltd on Tuesday said it has agreed to buy 51% stake in Guwahati-based Assam Hospitals Ltd for Rs.57.25 crore.

Assam Hospitals has a profitable 220-bed hospital in Guwahati. In a statement, Apollo Hospitals said it will upgrade and expand the capacity of the hospital to 300 beds. In the coming years, Apollo will introduce new services and offerings "built on its deep domain expertise," it said.

The hospital, situated on the Guwahati-Shillong Road, was started as a 50-bed facility in 2000. Currently, it has an occupancy level of over 80%. The promoters of Apollo Hospital decided to bring in a strategic partner to add value and strengthen its position in the northeast region, the statement said.

"In order to strengthen Apollo's position in the Northeast region, Apollo was on the lookout for acquisitions to grow inorganically and considers the acquisition as the right choice given its significant presence in the Northeast region," Suneeta Reddy, managing director of the company said in the statement.

Links: <http://www.livemint.com/Companies/5hpzLPgilQUsdLYBxaAyAM/Apollo-buys-stake-in-Assam-Hospitals.html>

---

## TRANSACTION NEWS

Date	Headlines	Summary
30-Jun	<b>Hinduja-Everstone consortium in the fray for Care Hospitals' stake, sources say (Source: Proprietary Intelligence)</b>	Care Hospitals' stake sale process has attracted bid interest from a consortium consisting of Hinduja Healthcare and Everstone Capital, three people familiar with the development said. A consortium consisting of South African hospital operator Netcare and Bain Capital has also bid for the controlling stake in the Hyderabad, India-based hospital chain, two of the people familiar said. Other bidders for Care Hospitals' stake include private equity firms TPG Growth, Temasek, Baring Asia and Abraaj Capital as well as one strategic each from southeast Asia and the Middle East, the first and second person said.
30-Jun	<b>Brazilian Silimed receives approaches as demand for breast silicone implants rises, CEO says (Source: Proprietary Intelligence)</b>	Silimed, the largest manufacturer of silicone breast implants in South America, is often courted by private equity firms, but it does not see an "immediate reason" to bring a financial investor on board, said Chief Executive Officer Gabriel Robert. The family-owned company is approached by financial investors at least 10 times per year and usually listens to their proposals, the executive said.
30-Jun	<b>Antworks to buy two US-based healthcare companies within 90 days – report (Source: Newswire Round-up)</b>	Antworks, a Singapore-based BPO company, will buy two US-based healthcare segment companies within 90 days, according to a newswire report. The Press Trust of India report cited Antworks' owner Asheesh Mehra. Between USD 8m and USD 10m will be spent on the planned acquisitions, according to the report. Antworks provides business process and technical solutions in financial services and healthcare. It has a centre at Pune, India.
30-Jun	<b>Nichiban could consider acquisition in East Asia or Southeast Asia - source (Source: Proprietary Intelligence)</b>	Nichiban [TYO:4218], a Tokyo, Japan-based taping products manufacturer, could consider an acquisition in East Asia or Southeast Asia to boost the sales volume of its medical and industrial taping products in the region, a source familiar with the situation said. The JPY 25bn (USD 209m) market cap company, which currently conducts marketing research on Southeast Asia through its Bangkok-based representative office in Thailand, is mulling an upgrade of its representative office to a subsidiary to engage in product distribution, the source said.
30-Jun	<b>Assessments Australia engages M&amp;A Partners to find buyer - source (Source: Proprietary Intelligence)</b>	Assessments Australia, a private Australian provider of healthcare assessment services, has hired corporate advisory firm M&A Partners to find a buyer, said a source familiar with the transaction. Information Memorandums (IMs) have been distributed to a number of potential buyers and the company is seeking non-binding indicative offers in the next couple of weeks, the source said.
30-Jun	<b>COL Capital says offer letter for 60.52% stake disposal in Lianyungang Jiatai Construction withdrawn (Source: Stock Exchange Announcement*)</b>	COL Capital (HKG:0383), the Hong Kong-listed financial services and property investment company, announced that the offer letter in respect of the disposal of its 60.52% equity interest in Lianyungang Jiatai Construction for CNY 907.8m (USD 146.3m) has been withdrawn: Reference is made to the announcement of COL Capital Limited (the "Company") dated 26 June 2015 (the "Announcement") in relation to a proposed disposal of a 60.52% equity interest in Jiatai Construction.
30-Jun	<b>Marksans Pharma acquires Time-Cap Laboratories (Source: Stock Company Press Release(s) (Edited))</b>	India-based Marksans Pharma (BSE: MARKSANS) has, through its wholly owned subsidiary, Marksans Pharma, Inc, acquired 100% of the outstanding shares of Time-Cap Laboratories ("Time-Cap"), a New York corporation having its principal office at 7 Michael Avenue, Farmingdale, New York.
30-Jun	<b>Tasly Pharmaceutical CNY 1.2bn five-year exchangeable bonds will be listed on 2 July (Source:</b>	Tasly Pharmaceutical [Tian Shi Li; SHA: 600535], a China based, listed pharmaceutical company, said tonight it has completed the issuance of CNY 1.2bn (USD 194m) five-year exchangeable bonds and the bonds will be listed on the Shanghai Stock Exchange on 2 July.

**Stock Exchange Announcement  
(Translated))**

30-Jun	<b>Zenotech Laboratories' committee of independent directors terms Sun Pharma's open offer 'fair and reasonable' at INR 20.87 per share (Source: Stock Company Press Release(s) (Edited))</b>	A committee of independent directors appointed by India's Zenotech Laboratories (BOM: 532039) has concluded that the open offer from Sun Pharmaceutical Industries (BOM: 524715) priced at INR 20.87 per share is both fair and reasonable, according to a stock exchange announcement. Sun Pharma previously announced an open offer for buying over 28% stake in Zenotech Laboratories.
29- Jun	<b>Zhongzhi Pharmaceutical to issue 200m shares at HKD 2.46 – HKD 3.08 per share in Hong Kong IPO (translated) (Source: Hong Kong Economic Times)</b>	Zhongzhi Pharmaceutical, a China-based pharmaceutical products manufacturer, plans to issue 200m shares at HKD 2.46 – HKD 3.08 per share in its Hong Kong IPO to raise HKD 492m (USD 63.5m) – HKD 616m, the online Hong Kong Economic Times reported. The Chinese language news report cited the company as saying that its share trading debut is slated for 13 July.
29- Jun	<b>Spinifex Pharmaceuticals to be acquired by Novartis for about USD 200m (Source: Company Press Release(s) (Edited))</b>	Spinifex Pharmaceuticals, Inc. ("Spinifex"), a company focused on the development of new drugs for the treatment of chronic pain, today (29 June) announced in a company press release that it has agreed to the sale of Spinifex to Novartis International AG ("Novartis"), for an upfront cash consideration of USD 200m plus undisclosed clinical development and regulatory milestone payments. The acquisition is centred on Spinifex's lead candidate EMA401, a novel angiotensin II type 2 (AT2) receptor antagonist, being developed as a potential first-in-class oral treatment for chronic pain, particularly neuropathic pain, without central nervous system (CNS) side effects.
29- Jun	<b>Samsung Bioepis to mandate managers to list on NASDAQ - report (translated) (Source: Korea Economic Daily)</b>	Samsung Bioepis, the biosimilar division of South Korea's Samsung Group, plans to launch an IPO on NASDAQ, Korea Economic Daily reported. The Korean language report cited investment bank sources as saying that the company will send request for proposals for an advisory mandate. The IPO would be launched in 1H16. A person from an investment bank was cited as saying that Samsung Bioepis is planning the IPO in order to fund KRW 1.5tn (USD 1.35bn) for biosimilar development.
29- Jun	<b>Zhongzhi Pharmaceutical may kick off Hong Kong IPO plan within this month – report (translated) (Source: Sing Tao Daily)</b>	Zhongzhi Pharmaceutical, a China-based pharmaceutical products manufacturer, may kick off its Hong Kong IPO plan within this month, according to an unsourced report in the Chinese language Sing Tao Daily. Zhongzhi Pharmaceutical reported a revenue of CNY 596m (USD 96m) in 2014.
29- Jun	<b>Echosens receives investment from Cathay Capital, OrbiMed and Chinese institutional investors (Source: Company Press Release(s) (Edited))</b>	Cathay Capital Private Equity, OrbiMed and several Chinese institutional investors acquired shares of Echosens SAS, a subsidiary of the FuRui group. The FuRui Group will retain a majority sharehold of 51% with Cathay Capital entering Echosens' shareholding structure in the context of a capital increase. Cathay Capital also subscribes for close to EUR 30m of newly issued company shares to finance its international expansion.
29- Jun	<b>Golden Meditech prepared to provide impairment provision of HKD 760m as disposal of Fortress Group will not proceed as contemplated (Source: Stock Exchange Announcement(s))</b>	Golden Meditech (HKG:0801), the Hong Kong listed, medical equipment company, announced that it is prepared to provide a full impairment provision of HKD 760m (USD 98m) as it has received a notice that the disposal of Fortress Group Limited will not proceed as contemplated: This announcement is made by Golden Meditech Holdings Limited (the "Company", and together with its subsidiaries, the "Group") pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) in relation to disclosure of inside information.

<b>29- Jun</b> <i>Evaheart seeks CROs for US and Europe clinical trials, would consider eventual IPO - exec (Source: Proprietary Intelligence)</i>	<i>Evaheart, Inc. (EVI), a privately held Texas-based medical device company, is seeking to retain one or two contract research organizations (CROs) for the clinical trials of its EVAHEART® Left Ventricular Assist System (EVAHEART® LVAS) in the US and Germany, President Tadashi Motomura said. EVI is currently in talks with a US-based CRO regarding those two trials. It, however, is still open to approaches from US- and Europe-based CROs, he continued. CRO candidates should have knowledge and experience in ventricular assist devices (VAD) and the ideal partner should have a dedicated team.</i>
<b>29- Jun</b> <i>Yestar International to net HKD 938.67m through share issue for acquisition purpose (Source: Stock Exchange Announcement(s))</i>	<i>Yestar International [HKG: 2393], a Hong Kong-listed color photographic paper products provider, announced that it has signed an agreement to raise net proceeds of approximately HKD 938.67m (USD 121m) through a share issue to 18 subscribers for acquisition purposes.</i>
<b>28- Jun</b> <i>COL Capital receives offer letter for 60.52% equity interest in Lianyungang Jiatai Construction (Source: Stock Exchange Announcement(s))</i>	<i>COL Capital (HKG:0383), the Hong Kong-listed financial services and property investment company, announced that it has received a legally-binding Offer Letter for its 60.52% equity interest in Lianyungang Jiatai Construction for CNY 907.8m (USD 146.3m). The principal business of Lianyungang Jiatai Construction is investment in and management and operation of healthcare and hospital businesses, trading of medical equipment and related supplies, and property development in PRC.</i>
<b>28- Jun</b> <i>Sichuan Gangtong Medical Equipment files Shenzhen IPO application with CSRC; Haitong Securities is sponsor/lead underwriter (Source: CSRC website)</i>	<i>Sichuan Gangtong Medical Equipment [Si Chuan Gang Tong Yi Liao She Bei], a Sichuan-based Chinese medical equipment maker, has filed its Shenzhen IPO application with the China Securities Regulatory Commission (CSRC). Haitong Securities is the IPO sponsor/lead underwriter. According to the CSRC website disclosure dated 26 June, the company plans to sell up to 25m shares via the initial public offering, with the aim of raising CNY 393.05m (USD 63.28m) to fund production base construction, technical center upgrade and to boost the operating capital of the company.</i>
<b>28- Jun</b> <i>Haisco Pharmaceutical subsidiary to buy 26.66% Medical Surgery Technologies stake (Source: Stock Exchange Announcement (Translated))</i>	<i>Haisight Investment, a subsidiary of Haisco Pharmaceutical Group [Hai Si Ke; SZ: 002653], a China based listed pharmaceutical company, has signed a Series C Share Purchase Agreement to buy a 26.66% stake in Medical Surgery Technologies (MST). According to a stock exchange announcement, Medical Surgery Technologies is an Israel-based advanced image-based laparoscope positioning system for minimally invasive surgical procedures. Haisight Investment will subscribe to 174,993 preferred shares of MST for USD 10.5m, taking up a 26.66% of fully diluted shares of the company.</i>
<b>28- Jun</b> <i>Tiansheng Pharmaceutical files CNY 1.079bn Shenzhen IPO application with CSRC, Huaxi Securities as sponsor/lead underwriter (Source: CSRC website)</i>	<i>Tiansheng Pharmaceutical [Tian Sheng Zhi Yao], a Chongqing-based, privately held pharmaceutical company, has filed its Shenzhen IPO application with the China Securities Regulatory Commission (CSRC); Huaxi Securities is the IPO sponsor/lead underwriter. According to the CSRC website disclosure dated 26 June, the company plans to sell up to 53m shares via the initial public offering and the IPO size is expected to be CNY 1.079bn (USD 174m) to fund production and boost its operating capital.</i>
<b>28- Jun</b> <i>Guiyang Xintian Pharmaceutical files CNY 329.95m Shenzhen IPO application; Zhong De Securities is sponsor/lead underwriter (Source: CSRC website)</i>	<i>Guizhou Xintian Pharmaceutical [Xin Tian Yao Ye], a Guiyang-based, privately held Chinese medicine company, has filed its Shenzhen IPO application with the China Securities Regulatory Commission (CSRC). Zhong De Securities is the sponsor/lead underwriter. According to the CSRC website disclosure dated 26 June, the company plans to sell up to 17.22m shares or a 25% stake via the initial public offering, and the IPO size is expected to be CNY 329.95m (USD 53.12m).</i>
<b>27- Jun</b> <i>IFC proposes to invest up to USD 7m for minority stake in Health Vista India (Source: Company website)</i>	<i>International Finance Corporation (IFC) has proposed to invest up to USD 7m for a minority stake in Health Vista India (“Portea” or the “Company”). This information is available here on the IFC website under the ‘Overview’ and ‘Sponsor/Cost/Location’ tabs. The proposed investment will be used to finance the expansion of the Company’s home healthcare services business in India and Southeast Asia.</i>

26- Jun	<b>Filter Vision in talks for M&amp;A; denies rumour on stake sale deal (translated) (Source: Thunhoon)</b>	Filter Vision [BKK:FVC], a Thailand-based water treatment systems provider, is in talks for a merger and acquisition deal of an unidentified medical company, Thunhoon reported. The Thai-language report cited MD Wichit Techakasem as saying that the company has discussed with the potential target and the deal may be finalized in the second half of this year.
26- Jun	<b>VetWest and Adelaide Animal Hospital receive investment from Mercury Capital - report (Source: Australian Financial Review)</b>	Mercury Capital has invested in VetWest, the Perth-based vet business, and Adelaide Animal Hospital, the Australian Financial Review's Street Talk column reported. According to the report, which did not cite sources, the deal was valued at around AUD 60m (USD 46.58m). The report said Mercury Capital will control 50% of the business with the other half owed by its founding partners.
26- Jun	<b>Bioton receives PLN 7-per-share bid from NovoTek for 33% stake (Source: Stock Exchange Announcement (Translated))</b>	NovoTek Pharmaceuticals Limited, headquartered in Hong Kong, has announced an offer for 28.33m shares, representing a 33% stake in listed Polish insulin maker Bioton, announced today Millennium Dom Maklerski, the intermediary in the transaction. The offered price is PLN 7 (USD 1.8) per share. NovoTek Pharmaceuticals intends to acquire shares exclusively if the amount of shares tendered for sale will be no less than 25.75m shares, entitling to 30% of total votes at the company General Meeting.
26- Jun	<b>Sparsha Pharma in talks with overseas strategics for USD 6m-7m fundraise (Source: Proprietary Intelligence)</b>	Sparsha Pharma International, a Hyderabad, India-based company, is in talks with overseas strategic players to raise USD 6m to USD 7m to build its manufacturing facility, said CEO Dangi Veerapaneni. The cash will be in exchange for a minority stake in the company, he added. It is receptive to strategic advisory approaches, he said. The company manufactures transdermal drug delivery systems and has around six products on the Indian market, primarily focused on pain medication for oncology patients.
26- Jun	<b>Guangzhou Baiyunshan Pharmaceutical to bid for 100% of Guangzhou General Pharmaceutical Research Institute (Source: Stock Exchange Announcement (Translated))</b>	Guangzhou Baiyunshan Pharmaceutical [Bai Yun Shan; SHA: 600332], a Guangdong-based, listed pharmaceutical company, said in a stock exchange announcement tonight that it will bid for 100% of Guangzhou General Pharmaceutical Research Institute. Guangzhou General Pharmaceutical Research Institute [Guang Zhou Yi Yao Yan Jiu Zong Yuan] has been put up for sale from 3 June to 1 July by Guangzhou Pharmaceutical Holdings [Guang Yao Ji Tuan] at CNY160.198m (USD 25.841m).
25- Jun	<b>Clearside Biomedical raising capital to fund lead program – CEO (Source: Proprietary Intelligence )</b>	Further fundraising expected in 2017 for commercialization IPO could also be considered at that time Strategic partners sought for licensing deals Clearside Biomedical, a venture capital-backed ophthalmic pharmaceutical company, recently embarked on a USD 35m capital raise, said CEO Daniel White. RBC Capital Markets has been retained by the Alpharetta, Georgia-based firm to handle the fundraising, which is targeting private equity firms in addition to VCs, according to White.
25- Jun	<b>Sienna Cancer Diagnostics plans to conduct dual-track AUD 20m fundraising this year – CEO (Source: Proprietary Intelligence)</b>	Sienna Cancer Diagnostics, an Australia-based privately held biotech company, plans to raise AUD 10m (USD 7.7m) in three months for cancer diagnostic reagent product development, Chief Executive Officer Cliff Holloway said. The deal would be featured with a 30% pre-IPO stake sale and Holloway hopes to conclude the fundraising by September. Proceeds will be used for R&D expenses and the company's European market entry, including Germany, United Kingdom, France and Italy, he said.
25- Jun	<b>Il Dong Pharmaceutical: H&amp;Q AP selected as preferred bidder in stake sale - report (translated) (Source: Korea Economic Daily)</b>	H&Q Asia Pacific, a California-headquartered and Hong Kong-based PE firm, has been selected as a preferred bidder in the sale of a stake in Il Dong Pharmaceutical, the Korea Economic Daily reported. Without citing a source, the Korean-language daily said the president has selected H&Q AP as the preferred bidder in the sale of a stake that the president will first acquire from Green Cross. The share price in the transaction is likely to be the same as the one for the deal between the president and Green Cross.
25- Jun	<b>Pure Pearl Group to buy three privately held hospitals at CNY</b>	Pure Pearl Group [Qian Zu Zhen Zhu; SZ: 002173], a China-based listed pearl producer and seller, said in a stock exchange announcement tonight that it plans to buy three

	<b>1.5bn, also planning fundraising via private placement (Source: Stock Exchange Announcement (Translated))</b>	privately held hospitals at an estimated CNY 1.5bn (USD 242m). Meanwhile, it plans to raise CNY 1.5bn via a private placement of new shares and the proceeds will be used to fund its business expansion into the medical services sector. The details are: Pure Pearl Group plans to buy the 100% each of Qiqihaer Jianhua Hospital [Jian Hua Yi Yuan], Haining Kanghua Hospital [Hai Ning Kang Hua Yi Yuan] and Jiangsu Futian Rehabilitation Hospital [Jiang Su Fu Tian Kang Fu Yi Yuan].
25- Jun	<b>Bionic Vision will consider IPO as it starts talks with investors for first clinical trial (Source: Proprietary Intelligence)</b>	Bionic Vision Technologies, a private Australian developer of bionic eye devices, is talking to investors for an AUD 10m (USD 7.7m) capital raise but will also equally consider a listing on the ASX, said executive chairman Robert Klupacs. The company's longer-term goal is to list on the ASX, and then possibly on the NASDAQ, Klupacs said. While a logical time for a listing would be when it receives its first clinical data, which is expected in 12-18 months, it will consider a listing now, Klupacs said, noting that some potential investors have indicated a preference for investing in a listed .
25- Jun	<b>Stericat Gutstrings' sale of controlling stake to France's Peters Surgical for USD 12m approved by India's FIPB (Source: Regulatory Authority Press Release (edited))</b>	The proposal from Peters Surgical, a French surgical suture specialist, to acquire a controlling stake in Stericat Gutstrings, a Gurgaon, India-based surgical sutures specialist, has been approved by India's foreign investment promotion board (FIPB), according to a regulatory announcement. According to the release from the FIPB, the proposal from Stericat Gutstrings to sell a 77.5% stakeholding to Peters Surgical (22.5% of which would be through share swap), has been approved.
24- Jun	<b>FTC requires Zimmer to divest assets to Smith &amp; Nephew and DJO Global as condition of Biomet acquisition (Source: Federal Trade Commission)</b>	Medical device company Zimmer Holdings, Inc. (NYSE and SIX: ZMH) has agreed to divest US rights and assets related to unicondylar knee implants, total elbow implants, and bone cement in order to settle FTC charges that its proposed USD 13.35bn acquisition of Biomet Inc. is anticompetitive, according to an FTC press release. Under the proposed settlement, the merged company will divest Zimmer's US ZUK unicondylar knee implant rights and assets to London-based Smith & Nephew, and Biomet's US Discovery Total Elbow implant and Cobalt Bone Cement rights and assets to Vista, California-based DJO Global, Inc.
24- Jun	<b>Mindray Medical forms special committee to review 4 June 'going private' proposal; retains Lazard (Source: Company Press Release(s))</b>	Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today that its board of directors has formed a special committee (the "Special Committee") comprised of three independent directors of the Company, Mr. Ronald Ede, Mr. Kern Lim and Mr. Qiyao Wu, to consider the previously announced non-binding proposal received by the Company's board of directors on June 4, 2015 from Mr. Li Xiting, its Executive Chairman of the Board, President and Co-Chief Executive Officer, Mr. Xu Hang, its Chairman of the Board, and Mr. Cheng Minghe, its Co-Chief Executive Officer and Chief Strategic Officer.
24- Jun	<b>Zhejiang Chimin Pharmaceutical, JD Capital to form a CNY 3bn pharmaceutical and medical services buyout fund (Source: Stock Exchange Announcement (Translated))</b>	Zhejiang Chimin Pharmaceutical [Ji Min Zhi Yao; SHA: 603222], a listed Chinese pharmaceutical company, and the Beijing-based PE JD Capital [Kun Wu Jiu Ding] plan to form a pharmaceutical and medical services buyout fund. According to the stock exchange announcement by the listed company, Jiuji Pharmaceutical and Healthcare Industry Investment Management Center, the proposed JV, is expected to manage funds of CNY 3bn (USD 483m).
24- Jun	<b>iKang Healthcare acquires Yantai Hongkang Tijian and Yantai Hongkang Jiankang Tijian (Source: Company Press Release(s) (Edited))</b>	iKang Healthcare Group, Inc. ("iKang" or the "Company") (Nasdaq:KANG), China's largest private preventive healthcare services provider, has acquired 100% equity interest in Yantai Hongkang Tijian Co. Ltd. and Yantai Hongkang Jiankang Tijian Co. Ltd. Each of the above company wholly owns a medical center specializing in medical examination services in the city of Yantai.

24- Jun	<b>Beacon Display in sale talks with Jingxin Pharmaceutical - sources say (Source: Proprietary Intelligence)</b>	Beacon Display [Ju Feng Ke Ji], a Shenzhen, China-based medical display device maker, is in sale talks with Jingxin Pharmaceutical (SHA:002020), a source familiar with the situation said. Shanghai-based Fosun Pharmaceutical had acquired a 15% stake in Beacon for a total of CNY 72.58m (USD 11.6m) in 2014, and is seeking an exit, together with Beacon's management who are the other major shareholders, the source said.
24- Jun	<b>Australia's Lake Imaging to use IPO proceeds for development, acquisitions - CEO (Source: Proprietary Intelligence)</b>	Australian medical diagnostics firm Lake Imaging plans to use proceeds from an initial public offering for development and acquisitions, CEO John Livingston said. Lake Imaging is keen on development and acquisitions in complementary markets in both regional and metropolitan areas across Australia, particularly those close to hospitals, Livingston said. It plans to fund the construction of entirely new facilities and to expand existing facilities, or add additional services.
24- Jun	<b>Arvida Group acquires three New Zealand retirement villages and aged care facilities (Source: Stock Exchange Announcement*)</b>	Arvida Group, the New Zealand-listed aged care business, has acquired three New Zealand-based retirement villages and aged care facilities, according to a stock exchange announcement. Arvida Group Limited (NZX:ARV) is pleased to announce the conditional acquisition of Aria Bay, Aria Park and Aria Gardens (collectively, "Aria Villages") for approximately NZD 62m (USD 42.4m). The Aria Villages comprise three high quality retirement villages and aged care facilities situated in premium locations across Auckland that provide retirement services to around 350 residents.
24- Jun	<b>Zhejiang Bangjie Digital Knitting Share, Sunshare Capital to form CNY 1bn medical buyout fund (Source: Stock Exchange Announcement (Translated))</b>	Zhejiang Bangjie Digital Knitting Share [Bang Jie Gu Fen; SZA: 002634], the Zhejiang-based, listed apparel company, said in a stock exchange announcement today that it plans to form a CNY 1bn (USD 162m) medical buyout fund with Sunshare Capital [Shang Xin Zi Ben]. Sunshare Capital is a Shanghai-based privately held investment company. According to the announcement, the fund will invest in medical services, pharmaceutical products and healthcare products sectors. The investment company plans to invest CNY 50m in the fund.
24- Jun	<b>Shanxi Zhendong Pharmaceutical plans major asset restructuring (translated) (Source: Stock Exchange Announcement (Translated))</b>	Shanxi Zhendong Pharmaceutical [Zhen Dong Zhi Yao; SZ: 300158] said in a stock exchange announcement on 24 June that it is planning a major asset restructuring and is expected to release the deal plan by 24 July. Shanxi Zhendong Pharmaceutical entered into a share trading suspension on 27 April due to an unspecified major issue. Today it confirmed that the major issue is related to a possible major asset restructuring.
24- Jun	<b>ShangPharma talks to underwriters for subsidiary listing; sets up drug development fund, sources say (Source: Proprietary Intelligence)</b>	ShangPharma, a Shanghai-based contract research organization (CRO), has been talking to underwriters for listing of its subsidiary China Gateway Life Science (CGLS) in the first half of 2016, said two company sources. China Gateway Life Science [Kai Hui Yao Ye], which provides contract manufacturing organization (CMO) services, aims to list on China's over-the-counter (OTC) board or Shanghai Stock Exchange's emerging industries board which is expected to be launched in early next year, said the first source.
24- Jun	<b>PuraPharm Corporation to raise up to USD 56.75m through Hong Kong IPO - report (translated) (Source: Hong Kong Economic Journal)</b>	PuraPharm Corporation, a Hong Kong-based Chinese medicine company, plans to issue 71.13m shares at HKD 5.16 – HKD 6.19 per share in its Hong Kong IPO to raise up to HKD 440m (USD 56.75m), the online Hong Kong Economic Journal reported. The Chinese language news report, without directly attributing its information to a source, added that the company will be listed on the Hong Kong stock exchange on 7 July.
24- Jun	<b>Serum Institute of India 20% stake to be sold by the Poonawalla group for up to INR 150bn, no plans for IPO (Source: The Hindu Business Line)</b>	India-based Poonawalla Group, which owns the Serum Institute of India (SII), an Indian vaccine maker, has plans to sell 20% stake in SII for INR 120bn-150bn (USD 1.89bn-2.4bn), The Hindu Business Line reported. Adar Poonawalla, executive director of SII, was cited for this information. The proceeds of the sale will be deployed to help fund the group's initiatives in other business verticals, including its real estate business.



24- Jun	<b>Lupin seen readying INR 75bn war chest for making acquisitions - report (Source: DNA)</b>	<i>Lupin (BOM: 500257), an Indian drug company, is reportedly planning to build a war chest with which to make acquisitions, DNA reported, citing undisclosed sources. Sources also said that Lupin is currently eyeing some big-ticket acquisitions, adding that the company may deploy the INR 75bn (USD 1.2bn) in capital, for which it recently received clearance for raising from its board, for this purpose. Lupin is eyeing both large and small-sized acquisition deals, one undisclosed source was further cited as saying. A big-ticket buy would be transformational for the company.</i>
23- Jun	<b>Lupin gets board approval to raise INR 75bn via securities issue, including equity shares (Source: Stock Exchange Announcement(s) (Edited))</b>	<i>Lupin (BOM: 500257), an Indian drug company, has received clearance from its board to raise INR 75bn (USD 1.18bn) via securities issue, according to a stock exchange filing. The release can be seen as follows: "Lupin Ltd has informed BSE that the Board of Directors, at their meeting held on 22 June 2015, approved in principle, the raising of funds up to INR 75bn through issue of Securities i.e.,</i>
23- Jun	<b>PuraPharm Corporation Hong Kong IPO sponsored by BOCOM International (Source: Stock Exchange Announcement*)</b>	<i>PuraPharm Corporation, a Hong Kong-based Chinese medicine company, has appointed BOCOM International to sponsor its Hong Kong IPO, according to a stock exchange announcement.</i>
23- Jun	<b>PuraPharm Corporation gains HKEx approval for IPO plan - report (translated) (Source: Hong Kong Economic Journal)</b>	<i>PuraPharm Corporation, a Hong Kong-based Chinese medicine company, has gained approval from the Hong Kong stock exchange for its IPO plan, the Hong Kong Economic Journal reported. The Chinese language news report, without directly attributing its information to a source, added that the company will kick off its IPO plan this week. <a href="#">Link to original source</a></i>
23- Jun	<b>Modern Family Doctor initiates up to USD 15m fundraise (Source: Proprietary Intelligence)</b>	<i>Modern Family Doctor, a private equity-backed, Bangalore-based primary care company, has initiated a third financing round to raise around USD 10m (INR 635m) to USD 15m, said founder Naresh Malhotra. The company is currently speaking with investment bankers to assign a mandate for the growth capital raise, Malhotra said. Its current PE-backers Saama Capital and Bamboo Finance may join the current process, he said.</i>
23- Jun	<b>Medibank's Workplace Health, Travel Doctor-TMVC businesses to be taken over by Sonic HealthPlus (Source: Company press release)</b>	<i>Medibank Private Ltd [ASX:MPL], an Australia-based private health insurance provider, will transfer its Workplace Health and Travel Doctor-TMVC Businesses to Sonic HealthPlus, according to a company press statement, as follows. Deloitte Corporate Finance were advisers to Medibank for the deal. The transfer of these businesses, which is subject to the completion of all necessary requirements, forms part of a review Medibank has undertaken of its Complementary Services businesses, which was highlighted in its Prospectus last year.</i>
23- Jun	<b>Healthscope Australian Pathology operations to be acquired by Crescent Capital Partners for AUD 105m (Source: Stock Exchange Announcement(s))</b>	<i>Healthscope Limited [ASX: HSO] has entered into an agreement to sell its Australian Pathology operations for AUD 105m (USD 81.5m) to Crescent Capital Partners, subject to standard completion adjustments. As part of the sale Healthscope will also transfer six skin clinics from its Medical Centre operations to Crescent. The consideration of AUD 105m will comprise cash proceeds of AUD 92.5m and a promissory note of AUD 12.5m. The transaction is scheduled to be completed by the end of July 2015.</i>
23- Jun	<b>Healthscope in final talks to sell pathology business to Crescent Capital – report (Source: Australian Financial Review)</b>	<i>Crescent Capital Partners is said to be in final talks to buy Healthscope's pathology business, the Australian Financial Review reported. According to the unsourced report in the paper's Street Talk column, the unit is anticipated to sell for around AUD 105m (USD 81.5m).</i>

23- Jun	<b>Health Care owner Archer Capital engages Luminis to explore sale options – report (Source: Australian Financial Review)</b>	<i>Luminis Partners has been engaged by Archer Capital to explore sale options for Health Care, the Australia-based hospital business, the Australian Financial Review reported. According to the unsourced report in the paper's Street Talk column, Luminis has been asked to gauge interest in Health Care among trade buyers, private equity, and financial players.</i>
22- Jun	<b>Hoan My Medical seeks co-investor to set up retirement resort business, source says (Source: Proprietary Intelligence)</b>	<i>Hoan My Medical, a Vietnam based private hospital operator, seeks a co-investor to set up a retirement resort venture, a company source said. The company, which is owned by the Singapore based investment firm Chandler Corporation, has 17.5 hectares of land in Dalat – the capital city in Lam Dong Province. It wants to develop a retirement resort which is a combination of independent living units and assisted nursing facilities. It wants an investor with expertise in retirement operations, said the source.</i>
22- Jun	<b>TPG, Carlyle may sell part of their combined 38% stake in Healthscope - report (Source: Australian Financial Review)</b>	<i>TPG Capital and the Carlyle Group, which own a combined 38% stake in Healthscope Ltd. [ASX: HSO], may sell a portion of their shareholding in the Australian hospital operator by offloading shares from escrow to mark up their profits for the second half-year period, the Australian Financial Review reported. The value of the combined stake is AUD 1.8bn (USD 1.4bn), and meetings between Healthscope CEO Robert Cooke and several potential strategic buyers in South East Asia are believed to have been held</i>
22- Jun	<b>Hugel mandates Korea I&amp;S as joint lead IPO manager, Hana Daewoo to act as co-manager - report (translated) (Source: The Bell)</b>	<i>Hugel, a South Korean botulinum toxin manufacturer, has mandated Korea Investment &amp; Securities as a joint lead IPO manager in addition to its earlier mandate of Daewoo Securities, reported The Bell. The Korean-language newspaper cited industry sources as saying that Hana Daetoo Securities will act as co-managers for the IPO. Hugel will apply for a regulatory review in August.</i>
22- Jun	<b>Guangdong Taiantang Pharmaceutical says Guangdong Kangaiduo Chain Drugstore planning NEEQ listing (Source: Stock Exchange Announcement (Translated))</b>	<i>Guangdong Taiantang Pharmaceutical [Tai An Tang; SZA: 002433], a listed pharmaceutical company in Guangdong, said tonight that its subsidiary Guangdong Kangaiduo Chain Drugstore [Kang Ai Duo] is planning a share reform and a listing on the National Equities Exchange and Quotations (NEEQ).</i>
22- Jun	<b>Alvogen bidder CVC-led consortium confirms controlling stake purchase (Source: Company Press Release(s) (Edited))</b>	<i>A consortium of investors led by CVC Capital Partners (“CVC”) and including Singapore-based investment company Temasek (“Temasek”) and Vatera Healthcare Partners (“Vatera”) have acquired a controlling stake in Alvogen, the high growth pharmaceutical company. An earlier related report by Reuters cited an unnamed source as saying that the deal values Alvogen at roughly USD 2bn. The release didn't give the deal value. The stake has been acquired from Pamplona Capital Management (“Pamplona”).</i>
22- Jun	<b>Alvogen controlling stake to be acquired by Temasek, CVC – CEO (Source: Newswire Round-up)</b>	<i>Alvogen, a New Jersey-based pharmaceutical business, will see its controlling stake acquired by CVC and Temasek, according to a newswire report. Reuters, citing Alvogen Chairman and CEO Robert Wessman, reported that the stake size in the potential transaction was not revealed. Citing an unnamed source, the report also said that the company will be valued at roughly USD 2bn in the deal.</i>
20- Jun	<b>Healthway Medical to be acquired by International Healthway through scheme of arrangement (Source: Stock Exchange Announcement*)</b>	<i>International Healthway Corporation (SGX:5WA), the Singapore-based healthcare services group, has announced the acquisition of Healthway Medical Corporation (SGX:5NG) through a scheme of arrangement, according to a stock exchange announcement. 1. INTRODUCTION 1.1. The Scheme. The Board of Directors of International Healthway Corporation Limited (the “Company” or “IHC”, and together with its subsidiaries, the “Group”) is pleased to announce the proposed acquisition (the “Acquisition”) by the Company of the entire issued and paid-up ordinary shares in the capital of Healthway Medical Corporation Limited (“HMC”, and together with its subsidiaries, the “HMC Group”) (the “HMC Shares”).</i>

20- Jun	<b>Sight Diagnostics to raise Series C round in 2016 (Source: Proprietary Intelligence)</b>	<i>Sight Diagnostics, an Israeli medical device company, could raise over USD 6m in mid-2016 to scale up production and finance clinical trials, co-founder and Chief Executive Joseph Pollak said. The size of the stake offered will likely be around 15% to 20%, he said. Founded in 2010, SightDx is developing a computer vision platform for blood disease diagnosis. Its first product - the Parasight Platform - is a rapid test for detecting malaria that is on the market in India and Africa.</i>
20- Jun	<b>Shaanxi Kanghui Pharmaceutical files CNY 690.03m Shanghai IPO application; Sinolink Securities as sponsor/lead underwriter (Source: CSRC website)</b>	<i>Shaanxi Kanghui Pharmaceutical [Shan Xi Kang Hui Zhi Yao], a Xianyang, Shaanxi-based, privately held pharmaceutical company, has filed its CNY 690.03m (USD 111.15m) Shanghai IPO application with the China Securities Regulatory Commission (CSRC). According to the CSRC website disclosure dated 20 June, Sinolink Securities is the IPO sponsor/lead underwriter.</i>
19- Jun	<b>Xuyi County Chinese Medicine Hospital 54.92% stake to be sold to Hengkang Medical Group for USD 20.34m (Source: Stock Exchange Announcement (Translated))</b>	<i>Hengkang Medical Group [Heng Kang Yi Liao; SZ: 002219], a Chinese pharmaceutical and healthcare company, has signed an agreement to buy a 54.92% stake in Xuyi County Chinese Medicine Hospital [Xu Yi Xian Zhong Yi Yuan] for CNY 126.3m (USD 20.34m). According to a stock exchange announcement posted on 19 June, Hengkang Medical Group will acquire a total of 54.92% stake in Xuyi County Chinese Medicine Hospital from Jiangsu Pengsheng Group and Xuyi County Xinlei Industrial and Trading.</i>
19- Jun	<b>Columbia Asia's shareholder EPF to revisit exit plans in three to four years (Source: Proprietary Intelligence)</b>	<i>Columbia Asia Group of Companies, the Malaysia-based hospital chains' shareholder Employees Provident Fund (EPF) will revisit exit plans in the next three to four years, Group Chief Executive Officer John Northen said. EPF did not respond to Mergermarket's email requesting comment. In early 2014, Columbia Asia sought to raise about USD 250m to USD 350m, as previously reported by this news service. It was working with Bank of America Merrill Lynch. The planned fundraising was to help buy back Malaysia's Employees Provident Fund (EPF), which owns a 30% stake in the company, according to the report. The EPF stake was valued at MYR 363.03m (USD 97.69m).</i>
19- Jun	<b>SOG to use bulk of funds from listing for acquisitions, JVs, CEO says (Source: Proprietary Intelligence)</b>	<i>Newly listed Singapore O&amp;G (SOG) [SGX: 41X], an obstetrics and gynaecology company, is eyeing acquisitions in Malaysia and Australia, Chief Executive Officer Victor Ng said. In addition, it is interested in forging joint ventures in China. The company plans to use SGD 6m (USD 5m) of the SGD 9.3m (USD 6.7m) listing proceeds for acquisitions and JVs. Approaches from sell-side advisers with targets that are independent sole proprietor.</i>
19- Jun	<b>Sandon Capital could further increase stake in Alchemia - source (Source: Proprietary Intelligence)</b>	<i>Sandon Capital [ASX:SNC], an Australian activist investment firm, could further increase its stake in biopharmaceutical company Alchemia [ASX:ACL], said a source familiar with Sandon Capital's investment strategy. In the past few weeks, Sandon Capital has increased its stake to 13%, the source noted. Its shareholding in Alchemia as of 20 May was 6.2%, as reported.</i>
19- Jun	<b>Enzychem Lifesciences plans KRW 50bn fundraise by Oct-end; will hire advisor for NASDAQ listing next year - CEO (Source: Proprietary Intelligence)</b>	<i>Enzychem Lifesciences, a listed South Korean biotechnology company, is seeking to raise KRW 50bn (USD 45m) from financial investors by the end of October, said CEO K.Y. Sohn. The company will raise the funds through a minority stake sale and the proceeds will be used for R&amp;D, he noted, without elaborating. The KRW 353.6bn market cap company wants to raise the capital from overseas funds, including Norway's Government Pension Fund Global (GPF), Netherlands-based pension fund manager APG and Singapore-based sovereign wealth fund Temasek Holdings, Sohn pointed out.</i>
18- Jun	<b>Shenyang Zhiying Medicine 70% stake to be sold to Yifan Xinfu Pharmaceutical (Source: Stock Exchange Announcement (Translated))</b>	<i>Yifan Xinfu Pharmaceutical [Yi Fan Xin Fu, 002019.SZ], a listed Chinese pharmaceutical company, has agreed to acquire a 70% stake in Shenyang Zhiying Medicine from Dianbai County Fuhong Investment for CNY 98m (USD 15.78m), according to a stock exchange announcement. Shenyang Zhiying Medicine, a large volume injection producer, booked revenue of CNY 84.38m and CNY 13m in 2014. Dianbai County Fuhong Investment is a privately owned investment company.</i>

18- Jun	<b>Xiangxue Pharmaceutical raises CNY 1.58891bn via rights issue (Source: Stock Exchange Announcement (Translated))</b>	Xiangxue Pharmaceutical [Xiang Xue Zhi Yao;CHI: 300147], a Guangdong-based, listed pharmaceutical company, has raised CNY 1.58891bn (USD 255.89m) via rights issue of new shares. According to the company stock exchange announcement, China Securities is the lead underwriter and a total of 151,903,006 new shares had been subscribed by the deadline of 16 June.
18- Jun	<b>Chipscreen mulls China OTC listing; approached by investors for funding, sources say (Source: Proprietary Intelligence)</b>	Chipscreen [Wei Xin Sheng Wu], a Shenzhen-based Chinese biopharmaceutical company, is considering a domestic listing this year after it completes an internal equity restructure this September, said two company sources. The board and the management team is still discussing the listing plan and prefers an over-the-counter (OTC) listing over a ChiNext listing. The procedure for the former is faster and Chipscreen does not currently meet the revenue demands of ChiNext as it only recently launched its first product, said one of the sources.
18- Jun	<b>Kawin Technology hires Haitong for A-share listing, sources say (Source: Proprietary Intelligence)</b>	China's Kawin Technology (Kai Yin Ke Ji), a biopharmaceutical company, has hired Haitong Securities to manage its potential A-share initial public offering, three sources familiar with the situation said. Beijing-based Kawin Technology is currently evaluating which board to list, two of the sources said, declining to give a timeline. But Kawin Technology has ruled out the option of listing on the over-the-counter market because the management team prefers to list on a larger board due to Kawin's current valuation, the first source said. Both the first and third source noted that the company has not yet determined a market for the listing.
18- Jun	<b>Shanghai SynTheAll Pharmaceutical completes more than CNY 500m fundraising, source says (Source: Proprietary Intelligence)</b>	Shanghai SynTheAll Pharmaceutical (He Quan Yao Ye) [NEEQ: 832159], a subsidiary of China-based Wuxi PharmaTech [NYSE: WX], has completed a more than CNY 500m (USD 80.6m) fundraising round, said a source familiar with the situation. Harvest Fund is among its new investors. Harvest Fund could not be reached for comment despite repeated calls. The source said the company also received investment from Hillhouse, Sequoia Capital and a PE fund affiliated to China International Capital Corporation (CICC), which were reported by this news service earlier this month as bidders interested in SynTheAll Pharmaceutical's fundraising.
18- Jun	<b>Strides Arcolab application to issue shares to foreign shareholders under proposed amalgamation of Shasun Pharmaceuticals with company rejected by FIPB (Source: Stock Exchange Announcement(s) (Edited))</b>	The India-based Strides Arcolab (BSE: STAR) has informed the BSE of the following. "The Company had made an application to the Foreign Investment Promotion Board (FIPB) of India seeking approval for issuing equity shares to non-resident shareholders of Shasun Pharmaceuticals (BSE: SHASUNPHAR) under the proposed Scheme of Amalgamation and the application was considered by the FIPB at its meeting held on 28 May 2015. The Press Information Bureau, Government of India, has issued a press release dated 17 June 2015 on the outcome of the FIPB meeting held on 28 May 2015.
18- Jun	<b>Amanjaya Specialist Centre being approached by financial and strategic investors, source says (Source: Proprietary Intelligence)</b>	Amanjaya Specialist Centre, a Malaysia-based, private hospital, is being approached by financial and strategic investors, a person familiar with the situation said. The private hospital operator could sell around a 30% to 40% stake to a financial investor as it looks to expand further, he said. The strategic investors include the large hospital operators in Malaysia that are interested in a 100% buyout. However, the company is not interested in completely selling out.
18- Jun	<b>Traditional Therapy Clinics seeking to raise AUD 15m in IPO (Source: Regulatory Authority Press Release)</b>	Traditional Therapy Clinics Ltd, an owner of Chinese health clinic, plans to raise AUD 15m (USD 11.6m) in an initial public offering in Australian through the issue of 30m shares under the offer, according to a prospectus lodged with ASIC. The offer is by way of a general public offer, a broker firm offer, an ASX bookbuild facility and an institutional offer of shares, the prospectus said, adding that the offer is not underwritten. The market capitalization is expected to be AUD 110.39m, the prospectus said.
18- Jun	<b>Cynvenio Biosystems closes USD 25.5m Series B equity financing led</b>	Cynvenio Biosystems, Inc., the pioneer in LiquidBiopsy technology for the genomic analysis of tumor cells from whole blood in support of cancer precision medicine

	<b>by Livzon Pharmaceutical (Source: Company Press Release(s))</b>	strategies, announced today the completion of a USD 25.5m Series B equity financing. Proceeds from the investment will be used to advance the company's clinical development and commercialization programs. The Series B round was led by Livzon Pharmaceutical Group, Inc. a diversified drug, diagnostics and healthcare company based in Zhuhai, P.R. China.
18- Jun	<b>Evolution Healthcare seeking to recapitalize via debt or equity investment, receives expressions of interest – report (Source: Australian Financial Review)</b>	Evolution Healthcare, the Australia-based hospital owner, is seeking a debt or equity investor for a recapitalisation to fund growth, the Australian Financial Review reported. According to the unsourced report in the paper's Street Talk column, interested groups are believed to have been asked to provide both debt and equity options valued at up to 75% of the business' value. The report noted that Evolution received expressions of interest from interested parties on Monday.
17- Jun	<b>China to further open medical institution sector to private investors (translated) (Source: Securities Times)</b>	China will further open its medical institution sector to private investors, according to a Securities Times report today (17 June). The item cited new regulations published by the China State Council as saying the government will encourage medical institutions backed up by private investors to seek funds for business operation via equity financing and project financing. In addition, the privately owned, profitable medical institutions will receive government support in gaining access to multiple means of fundraising, including IPOs and bond issuance.
17- Jun	<b>FMI, Lippo start USD 420m hospital JV in Myanmar – report (Source: Myanmar Business Today)</b>	First Myanmar Investments Co Ltd (FMI) and Lippo Group, an Indonesian conglomerate, has officially started the operations of their hospital joint venture in Myanmar with a USD 420m investment, Myanmar Business Today reported. The venture targets to have 12 hospitals in the country over the first three to five years, and to increase the number to 20 in 10 years, the item reported.
17- Jun	<b>Yunnan Hongxiang Yixintang Pharmaceutical subsidiary to buy 89 stores from Great Wall Pharmacy for as much as USD 38.65m (Source: Stock Exchange Announcement (Translated))</b>	Yunnan Hongxiang Yixintang Pharmaceutical [SZE: 002727], a Chinese drug distributor and retailer, said in a stock exchange announcement today that its Shanxi-based, wholly owned subsidiary plans to buy 89 stores from Great Wall Pharmacy Shanxi, a privately held pharmaceutical retailer. The deal value will be as high as CNY 240m (USD 38.65m).
17- Jun	<b>Shanghai New World signs LoI over buying remaining 40% stake in Cai Tong De Pharmaceutical (Source: Stock Exchange Announcement (Translated))</b>	Shanghai New World [Xin Shi Jie; SHA:600628 ], the listed Shanghai-based department store retailer, said today that it plans to acquire the remaining 40% stake in Cai Tong De Pharmaceutical [Cai Tong De Yao Ye] from its largest shareholder Shanghai New World Group. Cai Tong De Pharmaceutical is Shanghai-based pharmaceutical company. According to the Shanghai New World stock exchange announcement, Cai Tong De Pharmaceutical has total assets of CNY 463.9m (USD 74.68m) and net assets of CNY 131.65m.
17- Jun	<b>Hanwha Chemical selects Binex as preferred bidder in Osong medicine manufacturing operation sale (Source: Stock Exchange Announcement (Translated))</b>	Hanwha Chemical (KRX:009830), the listed South Korean chemical maker, announced today (17 June) that it has selected Binex (KOSDAQ:053030) as the preferred bidder in its planned sale of its Osong medicine manufacturing operation. Binex is a listed South Korean pharmaceutical company. This is according to a stock exchange announcement. As reported earlier, Hanwha Chemical was reportedly to put the medicine plant in the city of Cheongju, Chungcheongbuk-do in line with restructuring its biotechnology division.
16- Jun	<b>Kyongbo Pharma sets IPO share price at KRW 15,000 (Source: Stock Exchange Announcement (Translated))</b>	Kyongbo Pharmaceutical, a South Korean active pharmaceutical ingredients and finished dosages maker, announced today that it has set the offer price in its upcoming IPO at KRW 15,000 a share. It plans to raise KRW 143.4bn (USD 128.3m) in total from the IPO. Kyongbo will sell a total of 9,562,750 shares through the IPO and subscription will be open for two days from 18 June.

16- Jun	<b>China Renji Medical signs MoU for possible acquisition of an internet medical business in China (Source: Stock Exchange Announcement*)</b>	China Renji Medical (HKG:0648), a Hong Kong-based medical company, announced that it has signed a non-legally binding memorandum of understanding for the possible acquisition of a group of companies. The target group is principally engaged in the internet medical business in the PRC involving, among other things, (i) the provision of internet medical diagnosis/consultation services; (ii) the research and development of internet medical systems; and (iii) the design, development and production of the relevant internet medical equipment for use in the internet medical services.
16- Jun	<b>New Ray Medicine International will look for acquisition opportunities in future (translated)(Source: Infocast News)</b>	New Ray Medicine International [HKG: 6108], a pharmaceutical distributor based in China, will look for acquisition opportunities in the future, the Infocast News reported. The Chinese language news report, citing chairman Zhou Ling, said the company hopes to acquire businesses that will supplement its existing operations.
16- Jun	<b>Abano Healthcare to use NZD 30m for dental practices buys in FY16 (Source: Proprietary Intelligence)</b>	Abano Healthcare Group [NZE:ABA], the New Zealand-based healthcare and medical service provider, is planning to acquire 20 or more individual dental practices in FY16 as it seeks to grow its dental business that contributes about 75% to its gross revenues, said CFO Richard Keys, who will take over as CEO in October - November. Abano has between 1%-2% share of the Australian dental practice market and between 12%-15% share of the New Zealand one. The space is similar to a fragmented cottage industry dominated by independent individual practices, Keys said.
16- Jun	<b>Fakih and NMC Health spur growth of fertility clinics through M&amp;A (Source: Proprietary Intelligence)</b>	TVM Capital's Bourn Hall, Fakih and NMC Health main players in UAE fertility treatment Organic growth will be supplemented by acquisitions in fragmented market Roll-out of healthcare insurance among market drivers The surge in demand for in vitro fertility (IVF) clinics in the UAE has propelled sector players such as Fakih IVF Fertility Centre and NMC Health [NMC:LN] to engage in joint ventures and acquisitions, industry sources said. Another main player in the space is TVM Capital-backed Bourn Hall International, but there is space for all players to grow as the market is fragmented and there is scope for acquisitions, a source with knowledge of NMC Health's strategy said.
15- Jun	<b>Fleury minority stake being negotiated with Tarpon, Advent, KKR, Temasek, GIC – report (translated) (Source: O Estado de São Paulo)</b>	Core Participacoes, the controlling shareholder of Fleury (FLRY3: BZ), is in talks with investors such as Tarpon, Advent, KKR, Temasek and GIC to sell part of the Brazilian listed chain of medical diagnostic clinics, O Estado de Sao Paulo reported. The newspaper cited sources familiar with the situation as saying that at least 50% of Core Participacoes is being negotiated for a sale. Core owns, directly and indirectly, a 41.2% stake in Fleury, which has a market cap of BRL 2.8bn (USD 900m).
15- Jun	<b>Neoptics seeks CHF 10m via stake sale for new market entry – source (Source: Proprietary Intelligence)</b>	Neoptics AG, a privately held Swiss ophthalmic medical device company, plans to raise CHF 10m (USD 10.7m) via a stake sale this year to enter China, the US and Japan, a source said. The Hünenberg-based company is likely to sell up to a 27% stake for the capital raise, but could also consider selling a larger stake, the source added. It would welcome approaches from global strategic and financial investors, especially from Switzerland, China, Japan and the US. It has mandated financial advisors, including Cukierman & Co. Investment House for the plan, he noted.
15- Jun	<b>Medisupport to be acquired by Sonic Healthcare for USD 298m (Source: Stock Exchange Announcement(s) (Edited))</b>	Sonic Healthcare Limited [ASX: SHL] has signed binding agreements to acquire the Swiss medical laboratory group Medisupport S.A for CHF 277m (USD 298m). The (cash and debt free) purchase consideration represents a prospective (FY2016) EBITDA multiple of approximately 8 times, pre-synergies. The consideration will comprise CHF 277m in cash, funded from Sonic's debt facilities, and the issue of Sonic Healthcare ordinary shares. The transaction, inclusive of share issue, is expected to be accretive to Sonic's earnings per share by approximately 8% initially, and this is expected to increase further on realisation of synergies with Sonic's existing Swiss and European businesses.

<b>15- Jun InBody sells 5.01% stake to Wasatch Advisors for USD 203m (translated) (Source: Maeil Business)</b>	InBody, the listed South Korean medical equipment maker, sold a 5.01% stake to US-based Wasatch Advisors, for KRW 226.5bn (USD 203m), Maeil Business reported. The report cited information from Financial Supervisory Service (FSS) released on 14 June. CEO Cha Ki-Chul and three related members sold 685,000 shares (5.01%) to the financial investor on 9 June, the report said.
<b>15- Jun Hunan Er-kang Pharmaceutical to bid for Shandong Liaocheng A Hua Pharmaceutical 47.3% stake (Source: Stock Exchange Announcement (Translated))</b>	Hunan Er-kang Pharmaceutical [Er Kang Zhi Yao; SZ: 300267], a China-based listed company, has decided to bid for the 47.294% stake in Shandong Liaocheng A Hua Pharmaceutical [A Hua Zhi Yao] offered for sale by Shan Dong Dong-E E-jiao [Dong E E Jiao; 000423:SZ] As reported, Shandong-based, listed company Shan Dong Dong-E E-jiao has put a 47.294% stake in Shandong Liaocheng A Hua Pharmaceutical on the block at an initial bidding price of CNY 48.25m (USD 7.77m).
<b>14- Jun Jintian Pharmaceutical in discussion for potential acquisition of healthcare company (Source: Stock Exchange Announcement(s))</b>	Jintian Pharmaceutical Group (HKG:2211), a Hong Kong-listed China-based drugstore operator, announced that it is in discussion with certain independent third parties in relation to the potential acquisition of a healthcare company. As at the date of this announcement, no definitive terms have been agreed and no legally binding sale and purchase agreement has been entered into by the relevant parties.
<b>13- Jun Zhejiang Nutriease Health Technology files CNY 157m ChiNext IPO application with CSRC, Huafu Securities hired as sponsor/lead underwriter (Source: CSRC website)</b>	Zhejiang Nutriease Health Technology [Zhe Jiang Nuo Te Jian Kang Ke Ji], a privately held healthcare services company, has filed its ChiNext IPO application with the China Securities Regulatory Commission (CSRC). According to the CSRC website disclosure dated 12 June, Huafu Securities is the IPO sponsor/lead underwriter. The company plans to sell up to 17m shares or a 25% stake, with the aim of raising CNY 157m (USD 25.29m) to fund business expansion projects.
<b>13- Jun Universal Medical Services &amp; Health Management appoints Goldman Sachs and Nomura as joint sponsors for Hong Kong IPO (Source: Stock Exchange Announcement(s))</b>	Universal Medical Services & Health Management Company Limited, a China-based integrated healthcare solutions provider, has appointed Goldman Sachs and Nomura as joint sponsors for its Hong Kong IPO, according to a stock exchange announcement.
<b>13- Jun JOINN Laboratories files CNY 462.2m Shanghai IPO application with CSRC, Tebon Securities hired as IPO sponsor/lead underwriter (Source: CSRC website)</b>	JOINN Laboratories (Beijing) [Zhao Yan Xin Yao], a Beijing-based, privately held pharmaceutical R&D company, has filed a CNY 462.2m (USD 74.47m) Shanghai IPO application with the China Securities Regulatory Commission (CSRC). According to the CSRC website disclosure dated 12 June, Tebon Securities is the IPO sponsor/lead underwriter. The company plans to sell up to 20.5m shares via the initial public offering on the Shanghai Stock Exchange and the proceeds will be invested in new pharmaceutical R&D projects.
<b>13- Jun Zhejiang Starry Pharmaceutical files CNY 608.18m Shanghai IPO application with CSRC, Citi Orient Securities hired as sponsor/lead underwriter (Source: CSRC website)</b>	Zhejiang Starry Pharmaceutical [Zhe Jiang Si Tai Li Zhi Yao], a privately held pharmaceutical company, has filed its Shanghai IPO application with the China Securities Regulatory Commission (CSRC), according to the CSRC website disclosure on 12 June. Citi Orient Securities is the IPO sponsor/lead underwriter.
<b>13- Jun Tianyin Pharmaceutical unit forms CNY 200m JV with Buchang Pharma (Source: Company Press Release(s) (Edited))</b>	Tianyin Pharmaceutical Co., Inc. (TPI) [NYSE: TPI], a Chinese pharmaceutical company, further updated that the discussions between Chengdu Tianyin and Buchang Pharma have further developed towards increasing percentage of ownership by Buchang Pharma in the Tianyin-Buchang Alliance joint venture, according to a press release. The total registered capital for the joint venture is CNY 200m (USD 33m), of which the TPI's wholly owned subsidiary Chengdu Tianyin Pharmaceutical Co., Ltd.

<b>12- Jun Pharma Research Products receives approval for listing on KOSDAQ (Source: Stock Exchange Announcement (Translated))</b>	CThe Korea Exchange today announced that the application of Pharma Research Products to be listed on KOSDAQ has been approved in a review on 11 June. Pharma Research Products is a South Korea-based pharmaceutical company, that aims to raise up to KRW 111.2bn (USD 101m) from the IPO. Pharma Research Products booked sales of KRW 24.7bn (USD 22.5m) and a net profit of KRW 8.8bn last year.
<b>12- Jun ATGen files application for Kosdaq IPO (Source: Stock Exchange Announcement (Translated))</b>	ATGen, a privately held South Korean protein and antibody reagent developer, has filed an application to clear regulatory approval for an IPO. ATGen plans to float on KOSDAQ, according to a statement on the Korean Exchange on 12 June. The company aims to raise up to KRW 15bn (USD 13.5m) through the IPO. The CEO at the company is the largest shareholder with a 14.3% stake.
<b>12- Jun Novartis India denies report, says no notice received from principal shareholders regarding intention to delist shares (Source: Stock Exchange Announcement(s) (Edited))</b>	With reference to a report from ET NOW dated 11 June 2015 and captioned “Novartis AG said to explore delisting of \$380 mn Indian unit.”, Novartis India (BSE: NOVARTIND) has issued a clarification to the BSE in a stock exchange announcement: “We would like to clarify that the Company is not aware of the source of this news item, 'Novartis AG said to explore delisting of \$380 million Indian units', as mentioned in your letter. The board of the Company has not received any notice from the promoters (principal shareholders) of the Company, Novartis (VTX: NOVN), on its intention to delist the equity shares of the Company from the BSE.”
<b>12- Jun 3SBio will consider making acquisitions (translated) (Source: Takungpao)</b>	3SBio Inc (HKG: 1530), the Shenyang-based drug maker, will consider making acquisitions, the Takungpao reported. The Chinese language news report, citing CFO Tan Bo, said potential takeover targets are mainly located in China. However, it is also possible for the company to make overseas acquisitions, he said. 3SBio raised approximately HKD 4.17bn (USD 537.8m) through its Hong Kong IPO, after pricing the shares at HKD 9.1 apiece.
<b>12- Jun Vitaco brings in JPMorgan to test market's IPO interest – report (Source: Australian Financial Review)</b>	Next Capital has engaged JPMorgan for the potential IPO of Vitaco, the Australian healthy snack business, the Australian Financial Review reported. According to the unsourced report in the paper's Street Talk column Vicato's management is expected to meet with fund managers to gauge interest in the business. The paper said that Next is not expected to decide on the IPO until after August's reporting period.
<b>12- Jun Besunyen Holdings terminates term sheet to acquire medical business in China (Source: Stock Exchange Announcement(s))</b>	Besunyen Holdings, a Hong Kong-listed China-based therapeutic tea producer, announced that it has terminated the term sheet for the possible acquisition of Beijing Puxiang Investment Management: This announcement is made by Besunyen Holdings Company Limited (the “Company”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance.
<b>12- Jun Biop Medical to raise USD 3m ahead of potential exit in 18 months (Source: Proprietary Intelligence)</b>	Biop Medical, an Israeli medical device company, is looking to raise USD 3m, board member Dalit Landesman Milo said. The funds will be used for clinical trials and to support efforts to obtain US regulatory approval ahead of a potential exit in 18 months, he said. Founded in 2013, Biop Medical is developing optical probes for pre-cancer and cancer diagnosis, including for cervical cancer.
<b>12- Jun GluSense to raise USD 10m for implantable continuous glucose monitor device development (Source: Proprietary Intelligence)</b>	GluSense, an Israeli digital health company, plans to raise another round of capital from new and existing investors before a potential exit, Chief Executive Boaz Brill said. Management is in touch with potential investors and would consider additional approaches, he said. The company, which is developing an implantable continuous glucose monitoring (CGM) device for diabetic patients, could raise USD 10m in a minority stake sale in the next 12-24 months to finance clinical trials and finalize R&D efforts.
<b>12- Jun Sejahteraraya Anugrahjaya plans IDR 1trn rights offer to increase free</b>	Sejahteraraya Anugrahjaya [IDX:SRAJ] will soon begin shopping for financial advisers for a potential IDR 1trn (USD 75m) rights offer as part of a plan to increase free float, according a company source and two bankers with knowledge of the matter. The



	<b>float, source says (Source: Proprietary Intelligence)</b>	Indonesian hospital operator's majority shareholder, Tahir and his family, which owns Sejahteraraya Anugrahjaya in almost in its entirety, will give up their rights to subscribing to the new shares, and will offload part of their stake on the open market to help align the company with an Indonesia Stock Exchange (IDX) regulation demanding a minimum free float of 7.5% for listed companies by the end of 2015 at the latest.
12- Jun	<b>Venus Medtech to close Series C funding soon, sources say (Source: Proprietary Intelligence)</b>	Venus Medtech [Qi Ming Yi Liao], a Hangzhou, China-based artificial prosthetic heart valve developer, is to close its Series C funding round soon by raising tens of millions of US dollars, said a company source and a person familiar with the situation. It has secured a local private equity fund to be the investor and will announce the deal within two months, said the source and the person familiar.
12- Jun	<b>Broncus Medical to raise USD 50m for lung cancer device commercialization, source says (Source: Proprietary Intelligence)</b>	Broncus Medical, a California-based medical device producer for lung cancer treatment, is planning to raise up to USD 50m within two to three months, a company source said. Proceeds for this funding will be used for marketing as the company's two major products have received market approval from both the US Food and Drug Administration (FDA) and Chinese Food and Drug Administration (CFDA), said the source. The company welcomes Chinese investors to approach it for the deal, said the source.
12- Jun	<b>Town Health International Medical seeking acquisition opportunities in China and Taiwan (translated) (Source: Takungpao)</b>	Town Health International Medical [HKG:3886], a Hong Kong-based healthcare service provider, is seeking acquisition opportunities in China and Taiwan, the Takungpao reported. The Chinese language news report, citing CEO Ronnie Hui, said the company plans to use HKD 400m (USD 51.6m) – HKD 600m to make acquisitions this year.
12- Jun	<b>GenesisCare continues to consider AUD 1bn IPO (Source: Australian Financial Review)</b>	GenesisCare, the Australian radiology services business, is still considering a potential AUD 1bn (USD 768m) IPO, the Australian Financial Review reported. The paper cited GenesisCare managing director Dan Collins as saying that listing the business remains an option, despite the recent cancellations of high profile Australian IPOs, such as the insurance business Greenstone and IVE Group.
12- Jun	<b>Albedo acquires 51% stake in China iMyth Company (Source: Stock Exchange Announcement*)</b>	Albedo (SGX:51B), the Singapore-listed steel trader, has acquired a 51% stake in China iMyth Company, a Singapore-incorporated aesthetic medicine group, according to a stock exchange announcement. Albedo Limited, a Singapore-listed steel trading company, said today it bought a majority stake in a Taiwanese aesthetic medicine group, which would serve as a springboard for its expansion into China's fast-growing healthcare market. Albedo has agreed to buy a 51% stake in China iMyth Company Pte Ltd.
11- Jun	<b>Sinocare ends proposed major asset restructuring (Source: Stock Exchange Announcement (Translated))</b>	Sinocare [San Nuo Sheng Wu, 300298.CHI], a Chinese listed medical equipment maker, said in a stock exchange announcement on 11 June that it has decided to cancel a proposed major asset restructuring. As reported, Sinocare had entered into a share trading halt since April over a planned major asset restructuring.
11- Jun	<b>TalkMed acquires 30% in Hong Kong Integrated Oncology Centre Holdings (Source: Stock Exchange Announcement*)</b>	TalkMed (SGX:5G3), the Singapore-based medical haematology and oncology company, has acquired a 30% stake in Hong Kong Integrated Oncology Centre Holdings (HKH), a Cayman Islands incorporated owner of an oncology centre, according to a stock exchange announcement. 1. ENTRY INTO COLLABORATION AGREEMENT WITH ASIAN CANCER CENTERS A. INTRODUCTION The board of directors (the "Board") at Talkmed Group (the "Company") wishes to voluntarily announce that in line with the Company's existing business strategy and future plans with respect to expanding our repertoire of healthcare services and overseas expansion as set out in pages 29 and 113 of the Company's offer document dated 17 January 2014 ("Offer Document"), it had entered into a collaboration agreement ("Agreement") with Asian Cancer Centers ("ACC"), a company incorporated in Cayman Islands, on 9 June 2015 to invest in an integrated oncology center.

<b>11- Jun Novartis Indian unit may be delisted – report (Source: Newswire Round-up)</b>	Swiss pharma giant Novartis may consider a move to first buy up the shares it does not hold in Indian entity that offers both over the counter and prescription medications, according to a newswire. Bloomberg quoted people familiar with the developments and said the USD 400m-plus entity could see the Swiss parent buy up the 25% it does not hold in Novartis India. The Bloomberg report noted that the Indian unit's most widely sold product is the Galvus Met diabetes treatment.
<b>11- Jun MUNIN (HK) seeks USD 20m via minority stake sale for drug development, CFO says (Source: Proprietary Intelligence)</b>	MUNIN (HK), a privately-held cancer treatment and drug research company, is seeking to raise USD 20m via a 10% stake sale by the end of 2015 for anti-cancer drug development, Chief Financial Officer Hans Yeung said. Proceeds will be used over a 30-month timeframe to complete ongoing pre-clinical animal studies, clinical trials and file patent applications for the manufacturing of a drug that could suppress the growth of Cyr61 protein, which is essential for cancer cell growth, Yeung added.
<b>11- Jun Icure Pharm to list next year (translated) (Source: Korea Economic Daily)</b>	Icure Pharm, a privately held South Korean maker of medical treatment patch, plans to list next year, reported Korea Economic Daily. The Korean-language report cited Youngkwon Choi, the CEO at the company, who said in an interview with the paper that it will mandate an IPO manager this month.
<b>11- Jun Hugel to file for IPO in 3Q15 - report (translated) (Source: The Bell)</b>	Hugel, a South Korean botulinum toxin manufacturer, will resume its suspended IPO process, reported The Bell. The Korean-language newspaper cited venture capital sector sources who said Hugel had been in talks with financial investors to raise money through a private funding exercise, but that those talks did not appear to have gone smoothly.
<b>11- Jun Bayer to sell Diabetes Care business to Panasonic Healthcare for EUR 1.02bn (Source: Company Press Release(s) (Edited))</b>	Bayer AG has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation. The total consideration for the transaction is EUR 1,022m (JPY 138bn). The sale will include the leading Contour™ portfolio of blood glucose monitoring meters and strips, as well as other products such as Breeze™2, Elite™ and Microlet™ lancing devices. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the first quarter of 2016.
<b>11- Jun Kyongbo Pharma to raise up to KRW 143bn in IPO - report (translated) (Source: Chosun Ilbo)</b>	Kyongbo Pharmaceutical, a South Korean active pharmaceutical ingredients and finished dosages maker, is expected to raise up to KRW 143.4bn (USD 127.7m) from its upcoming IPO, Chosun Ilbo reported. The Korean language daily, which did not cite a source, said that the company's IPO size is said to be KRW 124.3bn - KRW 143.4bn (USD 110.7m-USD 127.7m). Kyongbo Pharmaceutical had filed an application to list on the main board of the South Korean Exchange in March.
<b>11- Jun CARE Hospitals' buyout race sees Netcare and Baring Asia emerge as leading bidders – report (Source: VCCircle)</b>	The race to buy controlling stake in India's CARE Hospitals has seen South Africa-based Netcare and private equity (PE) firm Baring Asia emerge as the leading bidders to secure the deal, VCCircle reported, citing sources with knowledge of the matter. One source was further cited as saying that the deal could see CARE Hospitals' PE owner Advent International, which currently holds over 75% stake in the company, sell its entire stake in the India-based hospital chain.
<b>9- Jun TMC Life Sciences to select investment bank to finance Thomson Medical Hub project – CEO (Source: Proprietary Intelligence)</b>	TMC Life Sciences [KLSE : TMCLIFE], the Malaysian healthcare company, is in the process of selecting investment banks to craft a financing plan to complete its Thomson Medical Hub, CEO Chiang Yin Wong said. The MYR 767.694 (USD 204m)-market cap company expects to assign a mandate later this fall and welcomes further proposals from Malaysian and international banks. The medical hub project, which is located on 1.6 hectares of freehold land in Johor Baru, a Malaysian town bordering Singapore, has gross development value (GDV) of MYR 900m (USD 239.1m), Wong said.

<b>9- Jun</b> <b>GTJA Investment seeking LPs for CNY 500m medical fund, source says (Source: Proprietary Intelligence)</b>	GTJA Investment, a Shenzhen, China-based venture capital fund, is seeking limited partners to raise a CNY 500m medical fund, a source close to the situation said. The new fund is co-founded by GTJA and listed diagnostic company Dian Diagnostic [300244:SHE], which announced last month that it will invest CNY 60m in a medical-focused investment fund with GTJA.
<b>9- Jun</b> <b>Cambwick Healthcare could consider trade sale to a strategic, CEO says (Source: Proprietary Intelligence)</b>	Cambwick Healthcare K.K. (Cambwick), a privately held Tokyo, Japan-based medical device developer, could consider a trade sale to a global medical device manufacturer or a global pharmaceutical company that will commercialize its product ElectroVitamin Therapy, President and CEO Keisuke Hirasawa said. Regarding an exit strategy for the co-founders, a trade sale is the most likely option as the company does not intend to pursue an initial public offering. The potential buyer should be able to market its ElectroVitamin in the US, Europe, Japan and possibly in other global markets, he added.
<b>9- Jun</b> <b>Cloudnine Hospitals in talks with investors for raising USD 47m (Source: Mint)</b>	Cloudnine Hospitals, an India-based infant and maternity care provider, has initiated talks for raising INR 3bn (USD 46.73m), mint reported. Kishore Kumar, Cloudnine Hospitals' chairman, was cited. According to the report, talks are under way with both new and existing investors in the company for raising the funds. The paper also said that Cloudnine Hospitals is seeking to partner with, or alternatively acquire, small-sized hospital units, apart from the company's own plans to grow organically.
<b>9- Jun</b> <b>PW Medtech says Warburg Pincus sold its entire 19.56% shareholding (Source: Stock Exchange Announcement*)</b>	PW Medtech (HKG:1358), a Beijing-based medical equipment maker, announced that its substantial shareholder, Warburg Pincus, has sold its entire 19.56% shareholding: This announcement is made by PW Medtech Group Limited (the "Company") in accordance with Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
<b>9- Jun</b> <b>Zhongzhu Holding share trading halt remains, planning to buy a medical equipment company (Source: Stock Exchange Announcement (Translated))</b>	Zhongzhu Holding [Zhong Zhu Kong Gu; SHA: 600568], a China-based listed real estate developer, said in a stock exchange announcement dated 9 June that its share trading halt, which started on 27 April, will remain on 12 June due to planning assets purchase.
<b>8- Jun</b> <b>Pa Shun Pharmaceutical International files for Hong Kong IPO; China Everbright Capital is sponsor (Source: Stock Exchange Announcement(s))</b>	Pa Shun Pharmaceutical International Holdings Limited, a China-based integrated pharmaceutical company, has filed for an IPO in Hong Kong, according to a preliminary IPO document posted on the Hong Kong stock exchange website. China Everbright Capital is the sole sponsor of the share offer.
<b>7- Jun</b> <b>Topchoice Medical Investment in share trading halt over planned significant assets restructuring (Source: Stock Exchange Announcement (Translated))</b>	Topchoice Medical Investment [Tong Ce Yi Liao; SHA:600763], a Zhejiang-based listed medical investment company, has been in share trading halt since 25 May and the company confirms that it is planning a significant assets restructuring. According to the company stock exchange announcement dated 6 June, its share trading halt will remain on 8 June and is expected to last for up to one month. The company has a market cap of CNY 17.693bn (USD 2.852bn).
<b>7- Jun</b> <b>Beijing Bohui Innovation Technology signs conditional agreement for buying 100% of Avion at USD 28m</b>	Beijing Bohui Innovation Technology [Bo Hui Chuang Xin; CHI. 300318], a listed Chinese special equipment manufacturer, signed a conditional agreement over buying the 100% of Advion, INC, a New York-based, privately held mass analyzer and othe relevant equipment maker, on 5 June. According to the stock exchange announcement by the

	<b>(Source: Stock Exchange Announcement (Translated))</b>	listed company dated 8 June, the acquisition will be made via its new formed wholly subsidiary, and the deal value will be USD 28m.
5- Jun	<b>FGK Clinical Research in preliminary talks for potential sale, would consider further approaches – MD (Source: Proprietary Intelligence)</b>	FGK Clinical Research, a privately held Munich, Germany-based contract research organization (CRO), is in preliminary talks with a US-based CRO business to sell the company, co-founder and Managing Director Edgar Fenzl said. However, it would consider further approaches from advisors, he added. The company was previously reported by this news service in 2012 to be in non-exclusive due diligence with a CRO. The ongoing early stage discussion is with a different company, he noted, declining to elaborate.
5- Jun	<b>Freedom Meditech to raise funds this year before assessing exit plans, exec says (Source: Proprietary Intelligence)</b>	Freedom Meditech, a San Diego, California-based company, plans to raise up to USD 12m before the end of the year, according to Sharad Mishra, director of corporate development. The funds will help the Southern California company commercialize its ClearPath diagnostic device and could be the last outside round prior to an IPO within 24 months, said the executive, who also noted there is takeout interest in the company.
5- Jun	<b>West Pharmaceutical looking for bolt-ons, CEO says (Source: Proprietary Intelligence)</b>	West Pharmaceutical Services (NYSE:WST) will look for bolt-on buys to bolster both its drug packaging and drug delivery segments, said newly appointed CEO Eric Green on the sidelines of the Jefferies Healthcare conference in New York this week. In its packaging segment, the Lionville, Pennsylvania-based company is looking for buys for both geographic expansion outside the US as well as capabilities, said Green. The company already has a presence in packaging in China and India and is interested in buys in South Korea and adjacent geographies. It would also look for buys to boost its drug delivery segment, said Green.
5- Jun	<b>Amicogen seeking to acquire 51% stake in Shandong Lukang Record Pharmaceutical from Shandong Lukang Pharmaceutical - report (translated) (Source: Maeil Business)</b>	Amicogen (KOSDAQ:092040), a listed South Korean biocatalyst and enzyme maker, is seeking to acquire a 51% stake in Shandong Lukang Record Pharmaceutical from Shandong Lukang Pharmaceutical (SHA:600789), the Maeil Business reported. Shandong Lukang Record Pharmaceutical is an unlisted Chinese pharmaceutical joint venture between Shandong Lukang Pharmaceutical and Shanghai Record Pharmaceuticals. The Korean-language report cited investment banking sources as saying that Amicogen has inked a memorandum of understanding with Chinese Lukang, and due diligence is under way. The estimated deal value is about KRW 28bn (USD 25.3m).
4- Jun	<b>Tianjin Chasesun Pharmaceutical to buy Beijing Choice Electronic Technology, Huzhou Zhanwang Pharmaceutical (Source: Stock Exchange Announcement (Translated))</b>	Tianjin Chasesun Pharmaceutical [Hong Ri Yao Ye; SZ: 300026], a Chinese listed company, has signed agreements to buy 100% of Beijing Choice Electronic Technology [Chao Si Gu Fen] and Huzhou Zhanwang Pharmaceutical [Zhan Wang Yao Ye] for CNY 1.569bn (USD 253m). According to a stock exchange announcement posted on 4 June, Beijing Choice Electronic Technology is engaged with R&D, production and sales of healthcare electronic products. Huzhou Zhanwang Pharmaceutical is engaged with production and sales of pharmaceutical excipients and API.
4- Jun	<b>Tibet Rhodiola Pharmaceutical plans major asset restructuring, share trading halted (Source: Stock Exchange Announcement (Translated))</b>	Tibet Rhodiola Pharmaceutical [Xi Zang Yao Ye; SH: 600211], a China-based listed company, will continue a share trading halt from 5 June over a planned major asset restructuring, according to a stock exchange announcement. Tibet Rhodiola Pharmaceutical entered into a share trading since 22 May due to an unspecified major issue. The listed company confirmed that it is planning a major asset restructuring.
4- Jun	<b>Antisense Therapeutics seeks partner for Phase IIb multiple sclerosis trial, CEO says (Source: Proprietary Intelligence)</b>	Antisense Therapeutics (ASX:ANP), an Australian antisense drug development company, is actively seeking a partner for a Phase IIb clinical trial for its ATL1102 Multiple Sclerosis (MS) treatment, said CEO Mark Diamond. A partnership deal could involve a capital tie-up, similar to Antisense Therapeutics' recently announced partnership deal with Trevose, PA-based US pharmaceutical company Cortendo for Antisense's ATL1103 drug for growth disorders like acromegaly.

4- Jun	<b>Guangzhou General Pharmaceutical Research Institute put up for sale with asking price of CNY 160m (Source: Chinese Equity Exchange Announcement)</b>	The 100% stake of Guangzhou General Pharmaceutical Research Institute [Guang Zhou Yi Yao Yan Jiu Zong Yuan] has been put up for sale from 3 June to 1 July. The asking price is CNY 160.198m (USD 25.841m), according to an announcement posted on Guangzhou Enterprises Mergers and Acquisitions Services. The vendor is Guangzhou Pharmaceutical Holdings [Guang Zhou Yi Yao Ji Tuan], a Chinese state-owned pharmaceutical company.
4- Jun	<b>Mega Lifesciences to form JV in Indonesia; eyes additional M&amp;As and JVs (translated) (Source: Kaohoon)</b>	Mega Lifesciences [BKK:MEGA], a Thailand-based nutritional product and prescription pharmaceutical product distributor, will form a joint venture with an unidentified local partner in Indonesia, Kaohoon reported. Citing CEO Vivek Dhawan, the Thai-language report said that the company expects to finalize the deal in 3Q15. Mega Lifesciences is also looking for partners for additional mergers and acquisitions as well as joint ventures for its business expansion, the item added.
4- Jun	<b>Mindray Medical International receives take private proposal at USD 30 per share (Source: Company press release.)</b>	Mindray Medical International Limited ("Mindray," NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter dated June 4, 2015 from Mr. Li Xiting, its Executive Chairman of the Board, President and Co-Chief Executive Officer, Mr. Xu Hang, its Chairman of the Board, and Mr. Cheng Minghe, its Co-Chief Executive Officer and Chief Strategic Officer (collectively, the "Buyer Group"), to acquire all of the outstanding shares of the Company not already owned by the Buyer Group in a going private transaction for USD 30.0 per American Depositary Share ("ADS", each ADS representing one ordinary share) or USD 30.0 per ordinary share in cash, subject to certain conditions.
4- Jun	<b>Shinva Medical Instrument to bring in PE shareholders for mixed ownership reform, sources say (Source: Proprietary Intelligence)</b>	Shinva Medical Instrument [Xin Hua Yi Liao; SHE:600587], the state-owned, Chinese medical device manufacturer and distributor, is bringing in two or three private equity firms to reduce state ownership in the company through a private share placement, said a person familiar with the matter at the company, and two people familiar with the situation.
4- Jun	<b>EBOS Group ready with NZD 100m war-chest for buys, could look at Asia in 12-18 months, CEO says (Source: Proprietary Intelligence)</b>	EBOS Group [NZX.EBOS], the New Zealand-based healthcare and animal care products company, will start actively looking for acquisition targets in Australia and New Zealand in FY16 with a war-chest of more than NZD 100m (USD 71m) at its disposal, Patrick Davies, chief executive officer said. It might look at some Asian countries for expansion after 12-18 months, he said without elaborating further.
3- Jun	<b>Harbin Gloria Pharmaceuticals signs LoI to buy Weikang Pharmaceutical Group and subsidiaries (Source: Stock Exchange Announcement (Translated))</b>	Harbin Gloria Pharmaceuticals [Yu Heng Yao Ye; 002437.SZ], a listed Chinese pharmaceutical company, has signed a Letter of Intent to buy stakes in Weikang Pharmaceutical Group and its subsidiaries for an estimated CNY 1.5bn (USD 242m). According to a stock exchange announcement dated 3 June, Weikang Pharmaceutical Group is a privately owned company which operates certain hospitals in Liaoning Province, China.
3- Jun	<b>Teshima approached for IPO, will focus on organic growth - CEO says (Source: Proprietary Intelligence)</b>	Teshima, a privately held, Gunma, Japan-based manufacturer of injection needles and hypodermic tubing, has been approached by financial advisors who suggested the company pursue an initial public offering, but the company remains focused on organic growth, CEO Yukiko Teshima said. The advisers had recommended an IPO as the company operates a profitable business, the CEO added. The company considered listing in Japan in the past but decided against it, as it did not find enough merit in such a move, she noted.
3- Jun	<b>Shanghai Fosun Pharmaceutical subsidiary to acquire 49% stake in Yulin Medical Group (Source: Stock</b>	Shanghai Fosun Pharmaceutical [SHE:600196; HKE:2196], the Shanghai-based, listed pharmaceutical company, said its wholly owned subsidiary Shanghai Yicheng Hospital Investment and Management will acquire a 49% stake in the new Yulin Medical Group. Yulin Medical Group [Yu Lin Yi Liao Ji Tuan] is a hospital management group currently owned by the Yulin government. According to the stock exchange announcement by the

	<b>Exchange Announcement (Translated))</b>	listed company today, Yulin Medical Group will hold a 51% stake in the new company via its hospital assets including Yulin No. 1 People's Hospital and Yulin No. 3 People's Hospital. Based on the agreement signed.
3- Jun	<b>Apollo Hospitals Enterprise to acquire 51% stake in Assam Hospitals (Source: Company Press Release(s) (Edited))</b>	The India-based Apollo Hospitals Enterprise (BSE: APOLLOHOSP) announced on 02 June 2015 that it has entered into definitive agreements for the acquisition of a 51% majority stake in the India-based Assam Hospitals, which runs a 220-bed profitable hospital in Guwahati. The acquisition would be for an overall consideration not exceeding INR 572.5m (USD 9m). The transaction would be subject to completion of due diligence, compliance of conditions precedent and other statutory formalities.
3- Jun	<b>Sinco Pharmaceutical plans USD 200m Hong Kong IPO in 3Q; Citi advising – report (translated) (Source: Apple Daily)</b>	Sinco Pharmaceutical, a China-based healthcare products manufacturer, plans to raise around USD 200m through listing in Hong Kong in the third quarter of this year, the Apple Daily reported. The Chinese language news report, citing an undisclosed market source, added that Citi is the arranger of the flotation.
3- Jun	<b>AsiaMedic 28% stake sold to Luye Medical (Source: Stock Exchange Announcement*)</b>	Shareholders representing a 28.15% stake of AsiaMedic (SGX:505), a Singapore-based, listed health screening and diagnostics company, have agreed to sell it to Luye Medical Group, according to a stock exchange announcement. The board of directors (the "Board") at AsiaMedic (the "Company") wishes to announce that today it was informed by Grandiflora ("Grandiflora") and Mr. Tan Wang Cheow (collectively the "Vendors" and each a "Vendor") that the Vendors today entered into a sale-and-purchase agreement with Luye Medicals Group (the "Purchaser") pursuant to which the Vendors agreed to sell, and the Purchaser has agreed to purchase, an aggregate of 95,431,396 ordinary shares representing approximately 28.15% of the issued and paidup share capital of the Company at a price of SGD 0.18 per share.
3- Jun	<b>Agappe Diagnostics on acquisition drive pursuant to closing fundraise (Source: Proprietary Intelligence)</b>	Agappe Diagnostics, a Kerala, India-based in vitro diagnostics company, has raised capital from private equity to fund the company's acquisition plans in India and Europe, said Founder and Managing Director Thomas John. John declined to specify the fundraising amount or to name the private equity but noted it was a minority stake dilution. This news service reported in 2008 that the company was looking to raise USD 25m in exchange for a 25% stake sale.
3- Jun	<b>Schnell Biopharma says largest shareholder in talks with potential bidders on stake sale (Source: Stock Exchange Announcement (Translated))</b>	Schnell Biopharmaceuticals (KRX:003060), a listed South Korean company, announced today, 3 June, that its largest shareholder has been in talks with multiple bidders on the potential sale of a stake. Answering a Korea Exchange query on the volatility of trading, Schnell said it has no explanation for the fluctuation in its share price or investor decisions.
3- Jun	<b>Nanjing Xinjiekou Department Store plans to sell remaining 10% Nanjing Xinbai Pharmaceutical stake to ShenZhen GTJA Investment (Source: Stock Exchange Announcement (Translated))</b>	Nanjing Xinjiekou Department Store [Nan Jing Xin Bai; SH: 600682], a China-based listed department store retailer, has completed the sale of a 90% stake in Nanjing Xinbai Pharmaceutical and is planning the sale of the remaining 10%. According to a stock exchange announcement by the listed company tonight, it is scheduled to complete the sale of 100% of Nanjing Xinbai Pharmaceutical in two phases.
3- Jun	<b>Auspherix needs to raise GBP 10m-GBP 15m in 18-24 months for anti-infective clinical trials (Source: Proprietary Intelligence)</b>	Auspherix, an anti-infectives company owned by Australian investors, will raise GBP 10m-GBP 15m (USD 15m-USD 23m) in 12 to 18 months for clinical trials, said Board Member Stephen Thompson, who is a partner at the company's venture capital backer Brandon Capital. The company, which has moved its headquarters to the UK from Australia, is seeking to hire an auditor in the UK and is currently in discussions with a number of firms, Thompson said.

<b>3- Jun</b> <b>China NT Pharma seeks listed JV partner to expand new drug portfolio, CFO says (Source: Proprietary Intelligence)</b>	China NT Pharma Group [HKG:1011], a pharmaceutical products distributor, is seeking joint venture partner to co-invest in new tumor and leukemia drug development, Chief Financial Officer Steve Chiu said. Partners should be Hong Kong or China-listed drug makers with extensive experience in drug development, he said. New drug candidates for oncology especially leukemia and central nervous system treatment would be the key area NT Pharma planning to explore, he said.
<b>3- Jun</b> <b>Australian Pharmaceutical Industries 12% stake on sale by Solomon Lew – report (Source: Australian Financial Review)</b>	The 12% stake in Australian Pharmaceutical Industries Ltd [ASX: API] held by billionaire Solomon Lew is on sale, the Australian Financial Review reported in its Street Talk column. Stockbroker Brent Potts of Blue Ocean Equities is said to be behind the sale, according to the report. Australian Pharmaceutical Industries has a market capitalization of AUD 890.4m (USD 680m).
<b>3- Jun</b> <b>Astellas Pharma and Anokion form new company to collaborate in type 1 diabetes and celiac disease (Source: Company Press Release(s))</b>	Astellas Pharma [TYO:4503] announced on 2 June it has formed a new company in Massachusetts with Switzerland-based Anokion to collaborate in type 1 diabetes and celiac disease. Key components of the agreement include: A new company, Kanyos Bio (“Kanyos”, location: Cambridge, MA), has been created to develop clinical candidates in the two selected indications, with an option for Astellas to add a third autoimmune indication as part of the collaboration.
<b>2- Jun</b> <b>Traphaco begins talks with potential investors as Mekong seeks exit, sources say (Source: Proprietary Intelligence)</b>	Traphaco [HOSE: TRA], a Hanoi-based pharmaceuticals company, is talking to potential investors as its private equity fund Mekong Capital seeks to sell its 24.99% stake, said three people familiar with the situation. Mekong Capital and Traphaco did not respond to comment. Talks have made slow progress as one of the barriers is the asking price, the people said.
<b>2- Jun</b> <b>Shenzhen Neptunus Bioengineering to buy remaining 49% Dongsen Medical stake for about USD 41m (Source: Stock Exchange Announcement (Translated))</b>	Shenzhen Neptunus Bioengineering [Hai Wang Sheng Wu; SZ: 000078], a China based, listed pharmaceutical company, has agreed to acquire a 49% stake in Henan Dongsen Medical [Dong Sen Yi Yao] for approximately CNY 256m (USD 41.3m) from its minority shareholders. According to a stock exchange announcement dated 2 June, Shenzhen Neptunus Bioengineering plans to acquire a 39% stake in Henan Dongsen Medical, a medicine distributor, from Nanyang Dongsen Investment Consultancy for CNY 203.85m, and a 10% stake from Nanyang Hongji Cultural Communication for CNY 52.27m.
<b>2- Jun</b> <b>Opal Biosciences to assess exit options in 18-24 months, could attract suitors prior – MD (Source: Proprietary Intelligence)</b>	Opal Biosciences, a public unlisted Australian anti-infective treatment developer, plans to pursue exit options in 18-24 months but could attract suitor attention prior to that, said MD Julie Phillips. It will require advisors and will assess advisory needs at that time and dependent on any deal requirements, she said. The company was spun out of Australian vaccine developer BioDiem in May this year to facilitate external investment and an exit without diluting existing shareholders, as well as to improve its valuation.
<b>2- Jun</b> <b>Shanghai SynTheAll Pharmaceutical to close fundraising soon, source says (Source: Proprietary Intelligence)</b>	Shanghai SynTheAll Pharmaceutical (He Quan Yao Ye) [NEEQ: 832159], a subsidiary of China-based Wuxi PharmaTech [NYSE: WX], is close to signing a fundraising deal and has secured several institutional investors, said a company source. It will make an official announcement by mid-June, he added. The company has drawn bidding interest from a number of well-known private equity investors, including US-based Hillhouse Capital.
<b>2- Jun</b> <b>UCB gets bids from Cipla and Lupin for its US-based generic drugs business - Newswire Round-up (Source: Newswire Round-up)</b>	Belgian biopharma UCB (EBR:UCB) has received bids from both Cipla and Lupin to acquire its generic drugs business in the US -- Kremers Urban Pharmaceuticals Inc, according to a newswire report. Bloomberg cited sources in-the-know on Monday for this information. The two Indian companies had submitted their first-round bids late in April, the item noted.
<b>2- Jun</b> <b>Nanjing Pharmaceutical terminates sale of 28.57% stake in Beijing Zhibo Bio-Medical Technology to Qingyun</b>	Nanjing Pharmaceutical [Nan Jing Yi Yao;SHA: 600713], a China-based, listed pharmaceutical company, announced that its board has decided to terminate the sale of a 28.57% stake in Beijing Zhibo Bio-Medical to Qingyun Qinglv Electronic Technology. No payment had been made by Qingyun Qinglv Electronic Technology as of 21 May.

**Qinglv Electronic Technology****(Source: Stock Exchange****Announcement (Translated))**

<b>2- Jun</b>	<b>Panacea Medical issues IMs for USD 18.7m capital raise (Source: Proprietary Intelligence)</b>	Panacea Medical Technologies, an Indian radiotherapy focused medical device maker, is actively looking for investors to raise INR 1.2bn (USD 18.7m) to fund the launch of new products.
<b>2- Jun</b>	<b>China Cord Blood appoints Houlihan Lokey (China) as IFA, Cleary Gottlieb Steen &amp; Hamilton, Maples &amp; Calder as legal counsel to advise on going private proposal (Source: Company press release.)</b>	China Cord Blood Corporation (NYSE: CO) ("CCBC," the "Company," "we," "us" and "our"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that the Special Committee of the Company's board of directors (the "Special Committee") has appointed Houlihan Lokey (China) Limited as its independent financial advisor, Cleary Gottlieb Steen & Hamilton LLP as its United States legal counsel and Maples & Calder as its Cayman Islands legal counsel. Meditech") to acquire all of the outstanding ordinary shares of the Company not already directly or indirectly owned.
<b>2- Jun</b>	<b>National Vet Care hopes to close pre-IPO placement by 30 June ahead of 8 July ASX lodgement – CEO (Source: Proprietary Intelligence)</b>	National Vet Care (NVC), an Australian veterinary clinic aggregator, is now aiming to launch an initial public offering on July 8 on the Australian Securities Exchange, CEO Tomas Steenackers said. It has named Mills Oakley as its legal advisor, Steenackers said. Wilson HTM and Shaw Stockbroking will handle the IPO, he said, confirming earlier reports. The company hopes to raise AUD 40m (USD 30.75m) in its initial public offering but aims to have raised half of the capital by 30 June, Steenackers said.
<b>2- Jun</b>	<b>SHC Capital Asia enters into sale and purchase agreement to acquire Tong Da Medical Device (Source: Stock Exchange Announcement*)</b>	SHC Capital Asia (SGX:565), the Singapore-listed group, has entered into a sale and purchase agreement to acquire China-based manufacturer of medical equipment and disposable medical supplies, Tong Da Medical Device, noted a stock exchange announcement. 1. INTRODUCTION Further to the announcement dated 26 March 2015 on the non-binding memorandum of understanding ("MOU") entered into by SHC Capital Asia Limited (the "Company" or the "Group") and the announcements dated 30 April 2015 and 15 May 2015 relating to the extension thereof, the board of directors (the "Board" or the "Directors") of the Company is pleased to announce that the Company had on 29 May 2015 entered into a sale and purchase agreement (the "SPA") with CUIKS Limited, MENGGS Limited, LILC Limited, JongkolTrakulyingcharoen, Flourishing Profits Venture Limited, Hong Liang and Teoh Sew Hock (collectively, the "Existing Vendors")
<b>2- Jun</b>	<b>Metro Pacific Investments plans to buy 15 hospitals (Source: Manila Standard Today)</b>	Metro Pacific Investments [PSE: MPI], the listed Philippine group, is planning to acquire up to 15 hospitals, the Manila Standard Today reported on Tuesday, 2 June. The newspaper cited David Nicol, the chief financial officer of MPI, who said that in order to reach the goal of owning a portfolio of hospitals with 5,000 beds, the company would acquire 15 hospitals.
<b>1- Jun</b>	<b>ALung working with Oppenheimer on Series C – CEO (Source: Proprietary Intelligence)</b>	ALung, a venture capital-backed medical device company, is engaged in a USD 12m Series C capital raise to fund ongoing commercialization of its Hemolung Respiratory Assist System (RAS), said Chairman and CEO Peter DeComo. Oppenheimer & Co. has been retained to handle the process. Existing investors have already committed USD 5m, according to DeComo. Series C funds are expected to take the Pittsburgh, Pennsylvania-based company through to October or November 2016, though ALung is already anticipating beginning another funding round process next spring.
<b>1- Jun</b>	<b>Ningbo Rui Bio-technology 51% stake to be sold to Dirui Industrial for USD 90m (Source:</b>	Dirui Industrial [Di Rui Yi Liao; SZ: 300396], the China-based listed medical equipment and test products company, has reached an agreement to acquire a 51% stake in Ningbo Rui Bio-technology [Rui Yuan Sheng Wu Ke Ji] for CNY 554.625m (USD 89.5m). According to a stock exchange announcement posted on 1 June, Ningbo Rui Bio-



	<b>Stock Exchange Announcement (Translated))</b>	technology is a manufacturer of in vitro diagnostic reagent products controlled by Zheng Lihong, an individual investor.
1- Jun	<b>Linical to retain law firms for Asia market entry, eyes Japan CRO acquisition – EVP (Source: Proprietary Intelligence)</b>	Linical, a listed, Osaka, Japan-based contract research organization (CRO), will look to hire local law firms when it enters new Asian markets including the Philippines, Malaysia, Hong Kong and mainland China, Executive Vice President Keigo Tsujimoto said. The company, which has a market capitalization of JPY 14bn (USD 113m), has just finished registering its Singapore office and aims to open offices in the aforementioned regions as soon as possible to expand its CRO business, President and CEO Kazuhiro Hatano noted.
1- Jun	<b>Columbia Pacific Management invests in Kaiyuan Orthopedic Hospital (Source: Company Press Release(s) (Edited))</b>	Columbia Pacific Management, one of the largest healthcare providers in Asia, with 28 hospitals in India and Southeast Asia and three senior care facilities in China, announced today (1 June) it is officially entering the China hospital market with a major investment in a 200-bed orthopedic hospital in Shanghai. The Seattle-based firm last fall announced it was building two 250-bed multi-specialty hospitals through its new China hospital arm, Columbia China, both set to open in 2018.
1- Jun	<b>Global Healthcare - May deals roundup (Source: Proprietary Intelligence)</b>	This is a roundup of the largest pending deals in the healthcare sector globally over the last month, according to Mergermarket data. The date shows the last update published by this news service. This list does not take into account deals that may have been completed but have not yet been made public.
1- Jun	<b>Luye Pharma terminates stake acquisition in Beijing Jialin Pharmaceutical (Source: Stock Exchange Announcement*)</b>	Luye Pharma (HKG:2186) announced that it has terminated the stake acquisition in Beijing Jialin Pharmaceutical: Reference is made to the announcement of Luye Pharma Group Ltd. (the “Company” and together with its subsidiaries, the “Group”) dated 27 August 2014 in relation to the Group’s proposed acquisition of equity interest in Beijing Jialin Pharmaceutical Co.,
1- Jun	<b>R-Tech Ueno could seek Japan peer acquisition to strengthen MRs, executive says (Source: Proprietary Intelligence)</b>	R-Tech Ueno, [JASDAQ: 4573], a Tokyo, Japan-based ophthalmology drug developer, could pursue a domestic acquisition of a peer to increase the number of its medical representatives (MRs) if it decides to market one of its orphan drugs under development on its own, Director of Business Management Division Koji Nakamura said. R-Tech Ueno has an internal sales force of MRs and an acquisition would help the company shore up its marketing efforts for orphan drugs in the domestic market, he noted, without elaborating further.
1- Jun	<b>Zim Laboratories could see Ashmore Alchemy exit within one year (Source: Proprietary Intelligence)</b>	Zim Laboratories, a Nagpur, India-based pharmaceuticals drug delivery manufacturer, could be brought to the market by its private equity backer Ashmore Alchemy within one year, said a source with knowledge and a person familiar with the company strategy. Zim is in the process of transforming itself from a Contract Manufacturing Organisation (CMO) to a company that has its own product portfolio, a second person familiar with the company said.
1- Jun	<b>Il Dong Pharmaceutical president in talks to sell 29.36% stake to financial investor - report (translated) (Source: The Bell)</b>	The president of Il Dong Pharmaceutical has been in talks with several potential buyers regarding a sale of a 29.36% stake in the listed pharmaceutical company, reported The Bell. The Korean news report cited an insider from the company as saying that Il Dong has mandated Kudos as a financial advisor for the deal.
1- Jun	<b>Luye Pharma in trading halt pending announcement regarding acquisition of equity interest in Beijing Jialin Pharmaceutical (Source: Stock Exchange Announcement(s))</b>	Luye Pharma (HKG:2186) made the following announcement to the Hong Kong stock exchange: At the request of Luye Pharma Group Ltd. (the “Company”), trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been halted with effect from 9:00 a.m. on Monday, 1 June 2015 pending the release of an announcement regarding the acquisition of equity interest in Beijing Jialin Pharmaceutical Co., Ltd.,

**1- Jun 3SBio details plan to list on Hong Kong stock exchange (Source: Stock Exchange Announcement(s))**

*3SBio Inc, the Shenyang-based drug maker, has announced the details of its plan to list on the mainboard of the Hong Kong stock exchange. A total of 606,100,000 shares, of which 90% being International Offer Shares and 10% Hong Kong Offer Shares, are to be issued in the Share Offer. The share price is to be set at a range from HKD 8.3 to HKD 9.1 per share.*

---

## DISCLAIMER

---

This Information Package is distributed by Quadria Capital Investment Management ('Quadria Capital') upon the express understanding that no information herein contained is proprietary or has been independently verified. Further, no representation or warranty expressed or implied is made nor is any responsibility of any kind accepted with respect to the completeness or accuracy of any information. Also, no representation or warranty is expressed or implied is made that such information in any respect as of any date or dates after those stated herein with respect to any matter concerning any statement made in this Information Package. Quadria Capital and its Managing Partners, employees, agents and consultants shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from, or for any omissions from the Information Package. All recipients of the Information Package should make their own independent evaluations and should conduct their own investigation and analysis and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers, as they deem necessary.

Where this Information Package summarizes the provisions of any other document, that summary should not be relied upon and the relevant documentation must be referred to for its full effect.



**Abrar Mir**  
Managing Partner

**Quadria Capital Investment Management Pte. Ltd.**  
3 Pickering Street, #01-68 Nankin Row, Singapore - 048 660  
D +65 6221 6939 M +65 8522 1033  
abrar.mir@quadriacapital.com | www.quadriacapital.com



**Amit Varma**  
Managing Partner

**Quadria Capital Investment Advisors Pvt. Ltd.**  
D1 Clarion Collection, The Qutab Hotel Complex, Shaheed Jeet Singh  
Marg, New Delhi – 110 016  
D +91 11 4194 5507 M +91 98 1838 5665  
amit.varma@quadriacapital.com | www.quadriacapital.com